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Summary 
Cell fate decisions occur through the switch-like, irreversible activation of fate-specifying genes. 
These activation events are often assumed to be tightly-coupled to changes in upstream 
transcription factors, but could also be constrained by cis-epigenetic mechanisms at individual 
gene loci. Here, we studied the activation of Bcl11b, which controls T-cell fate commitment. To 
disentangle cis and trans effects, we generated mice where two Bcl11b copies are tagged with 
distinguishable fluorescent proteins. Quantitative live microscopy of progenitors from these mice 
revealed that Bcl11b turned on after a stochastic delay averaging multiple days, which varied not 
only between cells but also between Bcl11b alleles within the same cell. Genetic perturbations, 
together with mathematical modeling, showed that a distal enhancer controls the rate of 
epigenetic activation, while a parallel Notch-dependent trans-acting step stimulates expression 
from activated loci. These results show that developmental fate transitions can be controlled by 
stochastic cis-acting events on individual loci. 
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Introduction 
 
During development, individual cells establish and maintain stable gene expression programs 
through the irreversible activation of lineage-specifying regulatory genes. A fundamental goal of 
developmental biology is to understand how and when these activation events are initiated to 
drive cell fate transitions. The concentrations of active transcription factors in the nucleus are 
crucial for embryonic patterning and progressive gene expression changes in development 
(Briscoe and Small, 2015; Davidson, 2010; Jaeger, 2011), and are often assumed to directly 
dictate rates of target gene transcription (Coulon et al., 2013; Estrada et al., 2016; Phillips, 2015). 
At the same time, an additional layer of epigenetic control mechanisms acts directly at gene loci 
on chromosomes, through chemical modification of DNA or DNA-associated histone proteins 
(Bird, 2002; Tessarz and Kouzarides, 2014), or regulation of chromosome conformation or 
packing in the nucleus (Felsenfeld and Dekker, 2012). Chromatin modification and accessibility 
changes are ultimately initiated by the binding and action of trans-acting factors; however, while 
these changes are often assumed to closely follow transcription factor changes, other recent work 
shows that epigenetic processes could occur slowly (Kaikkonen et al., 2013; Mayran et al., 
2018), and could introduce slow, stochastic, rate-limiting steps to gene activation, even when 
transcription factor inputs are fully present (Berry et al., 2017; Bintu et al., 2016). Despite much 
work, it has generally remained unclear what role, if any, epigenetic mechanisms play in 
controlling the timing and outcome of developmental gene activation and cell fate decisions. 
 
Epigenetic control is ordinarily difficult to disentangle from control due to changes in 
transcription factor activity. However, the two mechanisms can be distinguished by their effects 
on different gene copies in the same cell (Bonasio et al., 2010).  Control due to transcription 
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factor changes occurs in trans, and thus affects two copies of the gene in the same cell 
coordinately; in contrast, epigenetic mechanisms function at single gene copies, in cis, and thus 
could generate distinct activation states for different gene copies in the same cell, a concept that 
underlies the utility of X-chromosome inactivation and other systems as models for epigenetic 
gene control (Berry et al., 2015; Deng et al., 2014; Farago et al., 2012; Gendrel and Heard, 2014; 
Ku et al., 2015; Xu et al., 2006). For this reason, tracking both copies of a gene in the same cell 
with distinguishable fluorescent proteins can provide insight into the dynamics of cis and trans 
regulatory processes (Berry et al., 2015; Elowitz et al., 2002). 
 
Using this approach of tracking two gene copies, we have studied the developmental activation 
of Bcl11b, a key driver of T-cell commitment and identity. To become a T-cell, hematopoietic 
progenitors transition through a series of developmental states, where they lose alternate lineage 
potential and eventually commit to the T-cell lineage (Fig. 1A). T-cell lineage commitment 
requires the irreversible switch-like activation of Bcl11b, which serves to repress alternate 
lineage potential and establish T-lineage identity (Li et al., 2010; Liu et al., 2010).  Bcl11b is 
regulated by an ensemble of transcription factors, including Runx1, GATA-3, TCF-1, and Notch, 
which bind to multiple locations on the gene locus (Li et al., 2013; Kueh et al., 2016). However, 
even when these developmentally controlled transcription factors have been fully mobilized, 
Bcl11b activation occurs only after an extended time delay of ~4 days, allowing pre-commitment 
expansion of progenitors (Kueh et al., 2016). During activation, the Bcl11b locus remodels its 
epigenetic state, undergoing changes in DNA methylation and histone modification (Ji et al., 
2010; Zhang et al., 2012), nuclear positioning, genome compartmentalization and looping 
interactions (Hu et al., 2018), and expression of a cis-acting lncRNA transcript (Isoda et al., 
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2017). These observations suggest that the dynamics of Bcl11b activation could be determined 
by epigenetic processes as well as transcription factors. 
 
To separately follow two Bcl11b copies in developing cells, we engineered a dual-color reporter 
mouse, where the two Bcl11b copies are tagged with distinguishable fluorescent proteins. We 
then used quantitative live-cell imaging to follow Bcl11b activation dynamics in single 
progenitor lineages, along with mathematical modeling and perturbation experiments to dissect 
the relative contributions of cis- and trans- acting inputs to Bcl11b regulation. Our results 
revealed that activation of Bcl11b and consequent T-cell commitment require a stochastic, cis-
acting epigenetic step on the Bcl11b locus. This step occurs independently at the two alleles in 
the same cell, with a slow timescale spanning multiple days and cell cycles. A separate trans-
acting step, controlled by the T-cell developmental signal Notch, occurs in parallel with this cis-
acting step and provides an additional necessary input for Bcl11b activation. Finally, we found 
that over the course of development, T-cell progenitors lose the ability to activate the cis-
epigenetic switch, and as result, can progress to final differentiated states with only one Bcl11b 
locus stably activated. Together, these results show that intrinsically stochastic events occurring 
at single gene copies can determine the timing and outcome of mammalian cell fate decisions. 
 
Results 
 
Two Bcl11b copies show slow, independent activation in single progenitor lineages  
We generated a double knock-in reporter mouse strain, with an mCitrine yellow fluorescent 
protein (YFP) inserted non-disruptively in the 3’-untranslated region of one Bcl11b copy and an 
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mCherry red fluorescent protein (mCh) at the same site in the other copy (Figures 1B and S1).  
Both Bcl11b copies contain a floxed neomycin resistance cassette downstream of the fluorescent 
protein (Figure S1); however, we have shown conclusively, using Cre-mediated excision, that 
this cassette has no effect on Bcl11b activation (Kueh et al., 2016).  We isolated T-cell 
populations at different stages of development and differentiation directly from dual reporter 
Bcl11b mice, and measured the fraction of cells expressing Bcl11b from each allele at stages 
spanning the initial onset of Bcl11b expression (Figure 1C). As reported previously (Kueh et al., 
2016; Tydell et al., 2007), Bcl11b was inactive in early T-cell progenitors (ETPs), and began to 
turn on in the subsequent CD4, CD8 double negative (DN)2A stage, becoming expressed in all 
cells throughout the rest of T-cell development (Figures 1A and 1C). By DN2B and DN3 stages, 
the large majority of cells had turned on both Bcl11b copies. These transitions involve multiple 
cell cycles each, with about two days between late ETP and DN2A and about three days between 
DN2A and DN2B. However, in the DN2A compartment where Bcl11b gene activation begins, a 
significant fraction of the cells expressed only one copy of Bcl11b, with roughly equal fractions 
of cells expressing either the YFP or mCherry alleles (Figure 1C, arrowheads). This suggested 
that the two Bcl11b copies could turn on at different times in the same cell during development.   
 
To determine directly whether two Bcl11b copies switch on independently in the same cell, we 
used multi-day timelapse imaging to follow the two Bcl11b fluorescent reporters in clonal 
lineages of developing progenitors. We sorted individual Bcl11b-negative DN2A T-cell 
progenitors from dual Bcl11b reporter mice, and cultured them in vitro with OP9-DL1 stromal 
cells (Schmitt and Zúñiga-Pflücker, 2002), confining them in microwells to allow tracking of 
descendants of each progenitor over multiple days (Figure 2A).  The ~1 hour interval between 
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successive frames did not permit complete lineage tracking due to rapid cell movement (Movie 
S1), but still enabled mapping and visualization of all descendants, and determination of coarse-
grained lineage relationships (Figure 2B, C, bottom left). We used OP9-DL1 cells to present the 
Notch ligand DL1, a critical T-cell developmental signal, and included the supportive cytokines 
Interleukin (IL)-7 and Flt3 ligand (see Materials and Methods).  
 
We had previously shown that about three days are required for half of the cells in such DN2A 
populations to turn on any Bcl11b expression (Kueh et al., 2016). In theory, this delay could 
reflect requirement for activation of some additional transcription factor. However, even a novel 
transcription factor would be able to work on both alleles in parallel. Instead, strikingly, imaging 
revealed strongly asynchronous activation of the two Bcl11b copies in the same cell during this 
time period. Within single clonal lineages of progenitors, one copy of Bcl11b could switch on 
multiple days and cell generations before the other (Figure 2B-C, Movie S1), giving rise to 
distinct allelic expression states that persisted over multiple divisions. Similar percentages of 
cells activated Bcl11b-YFP first as compared to those turning on Bcl11b-mCherry first, 
consistent with independent activation (Figures 2D-E). The results from the same mice also ruled 
out any imprinting-type allelic bias. Furthermore, in some clones, the times at which a Bcl11b 
allele first turned on differed between progeny of a single cell (Figure 2C, 42 hrs), such that 
individual progenitors frequently gave rise to clonal descendants with multiple distinct states of 
Bcl11b allelic activation (46.7% heterogeneous after 4d, N=15, Figure S2A and S2B). Thus, the 
allelic bias developed at a clonal level. A substantial percentage (~40%) of all cells remained 
monoallelic in expression after 4d (Figures 2E), indicating that stochastic locus activation occurs 
with a slow time constant spanning multiple days. Furthermore, the fractions of cells 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/318675doi: bioRxiv preprint first posted online May. 10, 2018; 
8	  	  
monoallelically expressing Bcl11b-YFP or Bcl11b-mCh increased with the same dynamics, 
indicating that each locus is triggered with the same stochastic activation rate.  Taken together, 
these results suggest that timing of the Bcl11b activation switch – and the ensuing commitment 
to become a T-cell – is controlled independently at each Bcl11b allele by a stochastic and 
remarkably slow rate-limiting step. 
 
A distal enhancer modulates stochastic Bcl11b locus activation 
The stochastic transition of Bcl11b from an inactive to active state may be controlled by specific 
cis-regulatory DNA elements on the Bcl11b locus. Consistent with this idea, we found that 
graded changes in Notch signaling, GATA-3 activity, and TCF-1 activity alter the likelihood of 
all-or-none activation, rather than the amplitude of transcription (Kueh et al., 2016). Indeed, in a 
number of systems, cis-regulatory elements do not appear to control transcriptional amplitudes, 
but instead modulate the probabilities of all-or-none activation (Khan et al., 2011; Walters et al., 
1995; Weintraub, 1988). To test how stochastic activation of individual Bcl11b alleles may be 
controlled, we examined the effect of disrupting the one known positive cis-regulatory element 
region, which resides ~850 kb downstream of Bcl11b within a “super enhancer” at the opposite 
end of the same topologically associated domain (Li et al., 2013) (Figure 3A). This region shows 
distinctive histone marking and some T-lineage-specific transcription factor occupancy even 
before Bcl11b activation (Kueh et al., 2016), lies about 11 kb from the promoter of a Bcl11b-
associated lncRNA, and loops to the Bcl11b gene body in a T-cell lineage specific manner (Hu et 
al., 2018; Isoda et al., 2017; Li et al., 2013). Like the Bcl11b locus itself, this enhancer region is 
marked by H3K27me3 in non-T lineage cells (Li et al., 2013). 
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Using standard gene targeting, we deleted this distal ~2kb enhancer region on the Bcl11b-YFP 
allele, leaving the Bcl11b-mCherry allele intact, to generate Bcl11bYFPΔEnh/mCh dual reporter mice 
(Figures 3A and S1), and then analyzed resultant effects on YFP regulation in different T-cell 
subsets (Figures 3B-C, and S3-S4). These were analyzed either from established young adult 
Bcl11bYFPΔEnh/mCh mice (Figures 3B-C, S3, and S4A-B) or from adult chimeras populated with 
fetal liver cells from the F0 generation (Figure S4). The non-disrupted Bcl11b-mCherry allele 
served as an internal, same-cell control. At the ETP stage, essentially all Bcl11b alleles were 
silent, regardless of whether they had an intact or disrupted enhancer, as expected (Fig. 3B). 
During the DN2A and DN2B stages, the enhancer-disrupted Bcl11b-YFP allele showed 
dramatically reduced activation compared to the Bcl11b-mCherry allele in the same cell. 
Interestingly, at later developmental stages in the thymus and in peripheral T-cell subsets (CD4, 
Treg, CD8) a large fraction of cells showed expression of the enhancer-disrupted YFP allele, 
along with the wild type Bcl11b-mCherry allele (Figures 3B-C, S3-4), indicating that the 
targeted element is not indispensable for Bcl11b activation.  However, a small but significant 
percentage of cells still failed to activate the enhancer-disrupted allele, and instead persisted in a 
monoallelic state with only expression of the Bcl11b-mCherry allele (Figures 3B-C, and S3-S4). 
Monoallelic cells were found in memory as well as naïve T-cell subsets (Figure S3), implying 
that these monoallelically expressing cells are capable of immune responses, as expected from 
the normal phenotype of Bcl11b knockout heterozygotes. As shown in fetal liver chimeras, 
generation and persistence of Bcl11b-mCherry monoallelic cells due to the mutant Bcl11bYFPΔEnh 
allele were determined cell intrinsically (Figure S4). However, from flow cytometric profiles, 
cells that turned on the disrupted allele expressed it at normal levels, suggesting that the enhancer 
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mutation reduced the stochastic rate of Bcl11b activation, but not its expression level once 
activated.  
 
To directly test this hypothesis, we measured Bcl11b-YFP activation with or without enhancer 
disruption, by sorting DN2 progenitors with zero or one allele activated, culturing on OP9-DL1 
feeders, and analyzing activation dynamics of both alleles using flow cytometry. Consistently, 
enhancer disruption greatly reduced the fraction of cells that turned on Bcl11b-YFP, but did not 
perturb its expression level in cells that already successfully activated it (Figure 3D). Neither the 
wildtype nor the enhancer-disrupted allele reverted to silence after being activated. These results 
show that the deleted region within the distal Bcl11b super-enhancer works selectively, in cis, to 
accelerate the irreversible stochastic switch of the Bcl11b locus from an inactive to an active 
state.  
 
The activation of the enhancer-disrupted Bcl11b allele observed in many DN2B and later cells 
suggests that there are other cis-regulatory elements on the Bcl11b locus that can also promote 
stochastic locus activation. The extended intergenic gene desert between Bcl11b and the next 
gene, Vrk1, is rich in potential regulatory elements that could compensate for the loss of the 
deleted enhancer element in the cells activating the YFP allele (Hu et al., 2018). Alternatively, 
the intact enhancer at the mCherry-tagged locus in the same cell could activate the enhancer-
deleted Bcl11b locus in trans, but this was ruled out when we bred mice with the enhancer 
deletion to homozygosity (Bcl11bYFPΔEnh/YFPΔEnh). Progenitors from these mice were still able to 
turn on Bcl11b and to undergo T-cell development to CD4, CD8 double positive (DP) and single 
positive (SP) cells, and all the cells in these populations had normal levels of Bcl11b expression 
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(Figure S5). Thus, the enhancer we identified works together with other regulatory elements 
specifically to control Bcl11b activation timing. 
 
A parallel trans-acting step enables expression from an activated Bcl11b locus  
The known transcriptional regulators of Bcl11b—TCF-1, Gata3, Notch1 and Runx1—reach full 
expression prior to entering the DN2 stage, suggesting they are not limiting for Bcl11b activation 
in DN2 cells. The data presented above shows that cis-acting mechanisms substantially slow 
activation at individual alleles. However, additional trans-acting factors or post-translational 
changes in these factors could still limit the kinetics of Bcl11b activation, working either 
upstream of the cis-opening mechanism or as a separate, independent requirement. To gain 
insight into whether such trans-acting inputs are necessary to explain the observed dynamics, 
and how they could act together with cis-acting step, we developed a set of minimal models 
requiring the cis-activating step either alone or together with an additional trans-acting step (see 
Mathematical Appendix for model details). 
 
In the simplest “cis only” model, we assume that only the cis-activation step is required for 
Bcl11b activation in DN2 stage, with all required trans-acting steps having occurred prior to the 
ETP-DN2 transition (Figure 4A, left). Because cis-activation is controlled at each allele by a 
single rate constant, this model predicts a lag between the appearance of monoallelic cells, which 
require one cis-activation event, and the appearance of biallelic cells, which require two 
independent events (Mathematical Appendix). By contrast, in experiments, some biallelic cells 
accumulated immediately, without a substantial lag relative to monoallelic ones, resulting in a 
poor fit of the data to the cis-only model (Figure 4A). These results rule out the simplest cis-only 
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model, and suggest that additional trans events may still limit Bcl11b expression at the DN2 
stage.   
 
We next considered two models in which trans-acting events affect Bcl11b activation. In the 
“sequential trans-cis” model, a trans step must occur prior to the cis-activation step (Figure 4A). 
This trans step could represent activation of a factor or epigenetic regulator that is necessary for 
cis-activation. In the “parallel trans-cis” model, both cis and trans steps are similarly necessary, 
but can occur in either order (Figure 4A). In this case, the trans step could represent activation of 
a factor that drives Bcl11b transcription, but only from a cis-activated locus.  While our models 
only consider the DN2 stage, we note that they allow for some events to occur prior to the ETP-
DN2A transition (Fig. 4A, gray dotted arrows). When the trans-acting step is rate limiting, both 
of these models reduce biallelic lag by allowing the two alleles to turn on in relatively quick 
succession (in either model) or simultaneously (in the parallel model). For this reason, both the 
sequential and parallel trans-cis models reduced the lag prior to accumulation of biallelic cells, 
and hence fit the data significantly better than the “cis only” model  (Figures 4B, p < 0.01 for 
both models).  
 
While the sequential and parallel models show similar bulk behavior, they make divergent 
predictions about the distributions of mono- and bi-allelic expression states within clonal 
lineages.  For example, in the sequential model, silent progenitors are equally likely to activate 
one or the other Bcl11b allele, and are thus more likely to show mono-allelic expression from 
both alleles in single clones (Fig. 4C, “mixed monoallelic”). In contrast, in the parallel model, 
non-expressing progenitors could have one cis-activated but unexpressed Bcl11b allele due to 
absence of the trans step.  Clonal descendants of such cells would be predisposed to show mono-
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allelic expression from the same allele before activating the second (Fig. 4C, “single 
monoallelic”). Therefore, to discriminate between sequential and parallel activation models, we 
used Monte-Carlo methods to simulate the dynamics of Bcl11b activation in all descendants of a 
single starting cell over four generations for each of the two models (Mathematical Appendix), 
using the parameters that gave the best fits to the global time course data in Fig. 4A. Altogether, 
we generated and analyzed N=30,000 clonal lineages for each model.  
 
As intuitively expected, the sequential trans-cis model predominantly generated ‘mixed 
monoallelic’ clones containing cells with mono-allelic expression of both alleles, with or without 
biallelically expressing cells (Figure 4C-D, “mixed monoallelic”). These distributions reflect the 
most likely event trajectory in the sequential model, in which independent, unsynchronized cis-
activation events occur at each Bcl11b locus in different cells from a single ancestor. Within a 
cohort of clonal descendants competent to activate the cis-step, the first-activated allele choice 
occurs independently in each cell, generating multiple paths towards biallelic Bcl11b activation 
within a single clone.  By contrast, the parallel model generated a much smaller fraction of such 
“mixed monoallelic” clones, and predominantly generated clones in which monoallelic 
expression was restricted to the same allele across most cells (Figure 4C-D, “single 
monoallelic”). This intra-clonal bias arises when the cis-acting step at one locus precedes the 
trans-step, forcing still-inactivated DN2A precursors to preferentially activate that locus once the 
trans-acting event occurs (Fig. 4C). Because the rate of cis-activation is low (τc ~ 4-6 days), 
individual cells within a clone can monoallelically activate the same locus prior to full biallelic 
expression. Moreover, the parallel but not the sequential trans-cis model gave rise to a small 
fraction of clones that showed only bi-allelic expression (Fig. 4C-D, “bi-allelic only”), reflecting 
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the activation of the trans-limiting step in cells that had already undergone cis-activation of both 
Bcl11b copies. 
 
To discriminate experimentally between these two models, we quantified the distribution of 
Bcl11b allelic activation states generated in clonal lineages from progenitors starting with no 
Bcl11b activation, observed by timelapse microscopy as described above (Fig. 2).  Within a 
clone, we most frequently observed monoallelic expression from only one specific allele, with or 
without biallelically expressing cells (Fig. 4E “single monoallelic”, light green, 7/9 clones, 
Fig. S6; similar results observed over three independent experiments), but only rarely observed 
monoallelic expression from both loci within the same clone (Fig. 4E, “mixed mono-allelic”, 
gray, 1/9 clones). The observed percentage of “single monoallelic” expressing clones (7/9 = 
77%) was significantly greater than that expected from the sequential trans-cis model (20.4%, p 
< 0.005). Moreover, in one clone, we observed concurrent activation of both alleles (Fig. 4E), a 
behavior that would have been exceedingly rare in a sequential model (none observed in 30,000 
simulations). Together, these results suggest that a trans-acting step, acting in parallel with the 
cis-acting step, controls Bcl11b expression. 
 
Notch signaling controls the parallel trans-acting step in Bcl11b activation 
Notch signaling drives T-cell fate commitment and provides an important input for Bcl11b 
expression. While not required to maintain Bcl11b expression in committed cells, it acts earlier 
to enhance the probability of all-or-none Bcl11b expression at the DN2 stage and stabilize 
Bcl11b expression shortly after activation, preventing the re-silencing that still can occur in a 
small fraction of newly expressing cells (Kueh et al., 2016).  The Notch intracellular domain is 
diffusible in the nucleus, but could affect Bcl11b activation by modulating either the cis or trans 
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step in the parallel model. For example, Notch signaling could activate a trans factor that drives 
Bcl11b transcription from a cis-activated locus. Alternatively, Notch could affect the rate of the 
cis-activation process, for instance by enhancing the activity of chromatin-remodeling enzymes 
on the Bcl11b promoter or enhancer (cf. Fig. 3).  
 
To distinguish between these two potential roles of Notch, we analyzed the effects of Notch 
signaling withdrawal on Bcl1b allelic expression patterns and compared the results to predictions 
from the parallel trans-cis model.  For these assays, we first sorted DN2 cells with no expression, 
mono-allelic expression or bi-allelic expression of Bcl11b as initial populations, and then 
cultured them either on OP9-DL1 or OP9-control feeders to maintain or remove Notch signaling, 
respectively. After four days, we analyzed the resulting Bcl11b allelic expression states using 
flow cytometry (Fig. 5A).   
 
DL1 removal caused distinct shifts in the distributions of final Bcl11b allelic expression states 
across each of the starting cell states. For progenitors with no initial Bcl11b expression, DL1 
withdrawal decreased the total fraction of cells that subsequently expressed Bcl11b from either 
allele (from 0.9 to 0.5, sum of mono-allelic and bi-allelic expressing cells, Fig. 5A), consistent 
with previous results (Kueh et al., 2016). DL1 withdrawal differentially affected the mono-allelic 
expressing population, such that the ratio of mono-allelic to bi-allelic expressing cells fell from 
~0.8 to 0.4 (Fig. 5A). In progenitors starting with mono-allelic Bcl11b expression, DL1 removal 
inhibited expression of the initially silent allele, and led to inactivation of the initially expressing 
allele in a small fraction of cells (Fig. 5) (Kueh et al., 2016). As with the non-expressing 
progenitors, it also reduced the ratio of mono-allelic to bi-allelic expressing cells (Figures 5A, 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/318675doi: bioRxiv preprint first posted online May. 10, 2018; 
16	  	  
5B). Finally, in bi-allelic Bcl11b progenitors, most cells maintained expression despite Notch 
removal as expected (Kueh et al., 2016), but a small fraction (~0.06) lost expression of both 
Bcl11b alleles entirely, reverting directly from the bi-allelic to a non-expressing state (Fig. 5A, 
diagonal arrows). The distribution of non-expressing, monoallelic, and biallelic expressing cell 
states in the population in any condition can be represented as a point in a triangular region of 
allowed states in a single diagram (Fig. 5B), providing a visual summary of the effect of Notch 
withdrawal on the population (Figure 5B). 
 
We compared these effects of experimental Notch withdrawal with predicted effects of a step-
like perturbation in either the cis or the trans-acting steps (see Mathematical Appendix). In order 
to account for reversibility in Bcl11b activation observed upon DL1 removal (Fig. S7), each 
perturbation was assumed to both decrease the rate of the forward (cis or trans) step and increase 
the rate of a reverse step. Simulations of the resulting models generated distributions of Bcl11b 
allelic activation states from non-expressing, monoallelic, and biallelic starting populations, with 
no perturbation, or with perturbation of the cis or trans-acting steps.  
 
Perturbation of the cis-acting step decreased the total fraction of cells expressing Bcl11b from all 
initial cell populations, as expected. However, in contrast to experimental observations, this 
simulated perturbation increased, rather than decreased, the ratio of mono-allelic expressing cells 
to bi-allelic expressing cells (Fig. 5C). It also caused biallelic expressing cells to sequentially 
turn off Bcl11b one allele at a time, rather than simultaneously as observed experimentally. 
These results suggest that perturbation of the cis-acting step does not account for the observed 
effects of Notch withdrawal (Fig. 5B,C). 
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By contrast, perturbation of the trans-acting step in the model produced effects resembling Notch 
withdrawal. First, it decreased the ratio of mono-allelic to bi-allelic expressing cells for starting 
progenitors with no or mono-allelic Bcl11b expression. Second, it led to direct reversion of bi-
allelic expressing progenitors to a non-expressing state, without passing through mono-allelic 
intermediates (Fig. 5D, green arrows). Concurrent inactivation of both alleles is difficult to 
reconcile with Notch affecting independent (cis) effects at each allele, but is expected in 
response to removal of a trans-acting factor required for maintaining expression (Figure 
5B).  Additionally, we note that these observations were also inconsistent with Notch controlling 
a necessary trans-acting step occurring strictly prior to cis-activation, as postulated by the 
sequential trans-cis model (Figure S7).  In this case, progenitors that express one or both Bcl11b 
alleles would no longer be affected by Notch withdrawal, inconsistent with our observations 
(Figure 5B).  Taken together, these results strongly suggest that a separate Notch-dependent 
trans-acting event, occurring in parallel with Bcl11b locus activation, is necessary for Bcl11b 
activation and T-cell lineage commitment. 
 
Bcl11b activation can only occur over a limited developmental window  
Given the finite rate of cis- and trans-activation steps, all cells would be expected to eventually 
activate both Bcl11b copies. However, a small fraction of cells were consistently found to 
express Bcl11b monoallelically in thymic and peripheral T cell subsets (Figures 3B-C, S3, and 
S4). This result suggested that cells might lose competence to activate any still-silent Bcl11b 
locus as they develop. To test this hypothesis, we sorted monoallelically expressing cells from 
different developmental stages, cultured them in vitro on OP9-DL1 monolayers for four days, 
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and analyzed expression of both Bcl11b alleles (Fig. 6A). The already-active copy retained 
active expression throughout the assay, as expected. However, the frequency of activation of the 
initial silent Bcl11b allele varied strongly with developmental stage. Activation occurred 
efficiently at the DN2 stage (DN2A and DN2B combined) but dropped sharply as cells 
progressed to DN3 (~80% versus ~15% activated after four days, Figure 6A), and dropped even 
further at the double positive (DP) and CD4 single positive stages (~1.5% and 2.4%, 
respectively, Fig. 6A). Equivalent results were obtained regardless of whether the experiment 
started with active YFP and mCherry alleles (Fig. 6A). These results indicate that cis-activation 
of Bcl11b predominantly occurs during DN2 and DN3 stages. 
 
This DN2-stage preference for Bcl11b activation competence could arise from stage-specific 
activity of the identified distal enhancer. To test this hypothesis, we compared the activation 
kinetics of intact and enhancer-disrupted YFP alleles in sorted progenitors expressing only the 
Bcl11b mCherry allele. When the input cells were DN2 cells, the enhancer-disrupted YFP allele 
showed markedly less activation over the next four days than the intact YFP allele (70% versus 
32%, Figure 6B). However, using input cells sorted at the DN3 stage, no differences in activation 
propensity were observed, with both wildtype and disrupted enhancer alleles showing the same 
attenuated degree of activation (~17%). These results suggest that the Bcl11b enhancer works 
specifically to enhance cis-activation of Bcl11b at the DN2 stage.  
 
Discussion 
Stochastic epigenetic control switches have been described in yeasts, plants, and, more recently, 
constructed in synthetic systems (Berry et al., 2017; Bintu et al., 2016; Hathaway et al., 2012; 
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Keung et al., 2014; Xu et al., 2006), yet their roles in controlling fate decisions in vertebrate 
developmental systems are not well understood. Specifically, it is not clear when epigenetic 
states simply respond passively to ‘upstream’ developmental changes in transcription factor 
activity, and when they actively impose distinct temporal constraints on transcription factor 
effects. By separately following the two chromosomal copies of Bcl11b in single cells, we found 
that the decision to turn on Bcl11b, and the ensuing transition to T-cell fate, involves a 
stochastic, irreversible rate-limiting cis-activation step that occurs on the each chromosomal 
allele of the Bcl11b gene itself. The cis-acting step occurs at a low enough rate (𝑘! = (4.2±3.3)×10!!/hr, Figure 4A) to generate numerous monoallelically expressing cells as 
intermediates, and is stable enough to propagate the same monoallelic activation state through 
multiple rounds of cell division in individual clones. In particular, by generating delays of 
multiple days and cell generations prior to differentiation, the cis-acting switch also indirectly 
controls the overall degree of proliferation of the progenitor pool. These results thus demonstrate 
that stochastic, epigenetic events on individual gene loci can fundamentally limit the timing and 
outcome of mammalian cell fate decisions, as well as the population structure of the resulting 
differentiated population.  
 
Slow, stochastic Bcl11b activation is controlled by an enhancer far downstream from the Bcl11b 
promoter, on the opposite end of the same topologically associated domain.  Multiple known 
epigenetic changes that occur on the Bcl11b locus could participate in the processes whose 
dynamics we have measured here.  The distal enhancer could recruit chromatin regulators that 
clear repressive chromatin modifications from the Bcl11b locus.  In its silent state, the Bcl11b 
promoter and gene body are covered by DNA methylation and histone H3K27me3 modifications 
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(Hu et al., 2018; Ji et al., 2010; Zhang et al., 2012). Chromatin regulators recruited by the 
enhancer could disrupt repressive modifications in their vicinity, catalyzing a phase transition 
that results in cooperative, all-or-none removal of repressive marks on the entire gene locus 
(Larson et al., 2017; Strom et al., 2017).  As another possibility, the distal enhancer could recruit 
trans- factors that facilitate its T-lineage-specific looping with the Bcl11b promoter (Li et al., 
2013).  As Bcl11b turns on, its promoter establishes new contacts with the distal enhancer, 
resulting in de novo formation of an altered topological associated domain, with boundaries 
defined by these two elements (Hu et al., 2018; Isoda et al., 2017).  Trans- regulators of DNA 
loop extrusion that associate with the distal enhancer, whose binding may be facilitated by non 
long-coding RNA transcription (Isoda et al., 2017), may stabilize these looping interactions 
(Fudenberg et al., 2016; Nasmyth, 2001; Riggs, 1990; Sanborn et al., 2015). The evidence for 
such epigenetic differences associated with the Bcl11b locus in T and non-T have been known 
for some time, but the functional impacts of cis-acting mechanisms on locus activation dynamics 
has been unknown until now. Ultimately, any of these mechanisms that are rate-limiting will 
have to account for the stochastic nature of Bcl11b locus activation, its exceptionally long 
activation time constant, and its all-or-none, irreversible nature, demonstrated here.  Dissecting 
the molecular and biophysical basis of these striking emergent properties will be the subject of 
future investigation.  
 
Our mathematical models, together with perturbation analysis, further show that Bcl11b 
expression also requires a separate Notch signal-dependent trans- event that is needed in parallel 
with Bcl11b cis-activation. Given the comparable slow rate constants for parallel cis and trans 
steps in our model, it is expected that a substantial fraction of cells would undergo the cis-acting 
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step prior to trans-activation and observable Bcl11b expression.  It is even possible that the cis-
acting step could occur earlier, i.e. within the ETP stage or during the ETP-DN2a transition 
(Kueh et al., 2016). In fact, earlier cis-activation is consistent with previous results showing ETP 
stage-specific dependence on the transcription factors GATA-3 and TCF-1 in controlling Bcl11b 
locus activation (Kueh et al., 2016), as well as chromatin changes occurring at the Bcl11b distal 
enhancer already observed at the ETP stage (Isoda et al., 2017; Zhang et al., 2012). 
 
Slow, stochastic epigenetic switches, like the one described here, may allow cells to tune the size 
and composition of differentiated tissues.  By using trans-acting inputs that modulate activation 
probabilities, such epigenetic switches could translate differences in input duration to changes in 
the fraction of output cells activated (Bintu et al., 2016), a strategy that could enable tunable 
control of cellular proportions in a developing tissue or organ. Moreover, a striking aspect of this 
mechanism is its ability to generate populations of mature T cells that are mosaic in the status of 
their activation of the two Bcl11b alleles. Indeed, the differential distribution of monoallelically 
expressing cells that we see among distinct functional T-cell subsets suggests the potential of 
non-uniform allelic activity to alter function or selective fitness. The increased fraction of 
monoallelically expressing cells that appear when an enhancer complex is weakened is a strong 
phenotype at the single cell level that could be relevant to enhancer polymorphisms in natural 
populations, although its impact could easily be underestimated by more conventional gene 
expression analyses.  
 
Here, we have illustrated a general approach that can reveal the dynamics of epigenetic control 
mechanisms, determine their prevalence in the genome, and elucidate their functional roles in 
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multicellular organism development and function. Stochastic epigenetic switches, similar to the 
one uncovered here, may constitute fundamental building blocks of cell fate control circuits in 
mammalian cells. As cells transition from one developmental state to another, they undergo 
concerted transformations in the chemical modification states or physical conformations of many 
regulated genes. These changes could reflect more widespread roles for epigenetic mechanisms 
in controlling cell state transition timing.   
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Figure 1: Dual-color Bcl11b reporter strategy can reveal epigenetic mechanisms controlling T-
cell lineage commitment.  A) Overview of early T-cell development. Bcl11b turns on to silence 
alternate fate potentials and drive T-cell fate commitment.  ETP – early thymic progenitor; DN2 
– CD4- CD8- double negative-2A progenitor; DP – CD4+ CD8+; NK – natural killer; DC – 
dendritic cell.  B) Dual color Bcl11b reporter cells, where two distinguishable fluorescent 
proteins (YFP and mCherry) are inserted non-disruptively into the same sites on the two 
chromosomal Bcl11b loci.  C) Flow cytometry plots show Bcl11b-YFP versus Bcl11b-mCh 
expression levels in developing T-cell progenitors from dual Bcl11b reporter mice.  Arrowheads 
or boxes indicate cells expressing one copy of Bcl11b.  Results are representative of 3 
independent experiments. See also Figure S1. 
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Figure 2: Two copies of Bcl11b switch on independently and stochastically in the same cell in 
single lineages of T-cell progenitors. A-B) Bcl11b-negative DN2 cells derived from bone-
marrow progenitors were isolated by flow cytometry, cultured within microwells, and followed 
for 5 days using fluorescence imaging. Cells were then segmented using automated image 
analysis. B-C).  Dynamics of Bcl11b activation in two representative clonal progenitor lineages. 
Timelapse images (top) show developing T-cell progenitors from two representative clones 
(left), with segmented cell boundaries in white. Numbers (top left) indicate time in hours. Scale 
bar=10 microns. Trees (bottom left) show coarse-grained cell lineage relationships cells shown 
here.  Plots (center, lower rows) show Bcl11b-YFP and Bcl11b-mCh expression time traces in all 
cells from a single clone, with vertical gray bars indicating the time points of the image shown 
on the left. Horizontal lines indicate activation threshold. Colored scatterplots (bottom right) 
show time evolution of Bcl11b-mCh versus Bcl11b-YFP levels in single clones, from 0h (cyan) 
to 120 h (purple).  D) Heat maps show Bcl11b-YFP and Bcl11b-mCh distributions in the 
polyconal population at the indicated time points.  White lines represent Bcl11b expression 
thresholds.  Color bar (left) represents normalized cell numbers at each time point.  E) Fractions 
of cells having different Bcl11b allelic expression states, obtained by mixed Gaussian fitting of 
the heat maps shown.  Data represent a cohort of ~200 starting cells from a single timelapse 
movie. Overall, data show that Bcl11b switches on slowly and stochastically in single lineages of 
progenitors, maintaining alternate activity states in the same clone, heritable across many 
divisions.  Results are representative of 3 independent experiments. See also Figure S2 and 
Movie S1. 
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Figure 3:  A distal enhancer region controls Bcl11b activation probability.  A) Schematic of 
normal and enhancer-deleted two-color Bcl11b reporter strains (left).  Genome browser plots 
(right), showing +850kb enhancer of Bcl11b, showing distributions of histone marks (H3K4me2, 
H3K27me, and H3K27Ac) and an associated LncRNA (Isoda et al., 2017). Orientation is with 
transcription from left to right (reversed relative to genome numbering). Gray shaded area 
indicates the enhancer region deleted using gene targeting (removed region: chr12:108,396,825-
108,398,672, mm9).  B) Flow cytometry plots show Bcl11b-mCh versus Bcl11b-YFP levels in 
developing T-cell populations from dual Bcl11b reporter mice, either with an intact YFP 
enhancer (top), or a disrupted YFP enhancer (bottom). Results are representative of 2 
independent experiments. C) Bar graphs showing the percentages of cells in early thymic 
populations with mono- and biallelic expression of wildtype mCherry and wildtype versus 
mutant YFP in wildtype Bcl11bYFP/mCh and Bcl11bYFPΔEnh/mCh dual reporter mice, demonstrating 
the loss of mutant YFP allele expression relative to the wildtype mCherry allele in the same 
cells. Each bar shows results from one mouse; n = 4 mice of each strain are shown. D) DN2 
progenitors were sorted for different Bcl11b allelic activation states as indicated, cultured on 
OP9-DL1 monolayers for 4 days, and analyzed using flow cytometry.  Flow plots show Bcl11b-
mCh versus Bcl11b-YFP levels of cells generated from precursors with a normal (top) or 
disrupted (bottom) YFP enhancer, showing defective YFP up-regulation from the mutant relative 
to the wildtype alleles. Enhancer disruption reduces the probability of switch-like Bcl11b 
activation, but does not affect expression levels after activation. Results are representative of 2 
independent experiments.  See also Figures S1, and S3 – S5. 
 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/318675doi: bioRxiv preprint first posted online May. 10, 2018; 
26	  	  
Figure 4:  A trans-acting step, occurring in parallel with the cis-acting step, provides an 
additional input for Bcl11b activation. A) Candidate models for Bcl11b activation from the DN2 
stage, involving a single cis-acting switch (top left), sequential trans-, then cis-acting switches 
(bottom left), and parallel, independent trans- and cis- acting switches (right).  Plots show best 
fits of different models to the time evolution of Bcl11b allelic activation states, observed by 
timelapse imaging (Figure 2), with best fit rate constants indicated in legend.  B) Bar charts show 
sum-squared errors for model fits, showing that both sequential and parallel trans-cis models fit 
the data significantly better than the cis-only model (F-test, F=17.4, p=0.0055, sequential vs. cis-
only model; F=8.5, p=0.007, parallel vs. cis-only model). C) Three possible classes of Bcl11b 
activation states observable from clonal lineage data.  Lineage trees and transition diagrams 
show examples of simulated lineages that fall into the indicated classes. D) Pie charts show 
expected distribution of allelic activation states predicted for clonal lineages of non-expressing 
progenitors in either the sequential (left) or the parallel (right) trans-cis model, obtained from 
N=30,000 simulations, using parameters derived from bulk fitting (see Mathematical Appendix). 
E) Pie chart (left) shows observed distribution of activation states observed across an entire 
imaging time course.  Colored scatterplots (right) shows Bcl11b-mCh versus Bcl11b-YFP levels 
of single cell lineages, falling into the indicated categories. Clones were scored according to 
observable fluorescence across an entire developmental trajectory, from 0h (cyan) to 120 h 
(purple). The observed frequency of clones with ‘single-monoallelic’ expression of Bcl11b 
(7/9=77%) is significantly different than that predicted for the sequential trans-cis Model 
(20.4%, **- p<0.001, χ2 = 14.5, d.f. = 1), but not significantly different from that predicted for 
the parallel trans-cis Model (68.9%, χ2 = 0.1, d..f=1, n.s.).  Results are representative of three 
independent experiments.   See Figure S6 for data for independent replicate experiments. 
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Figure 5:  Notch signaling controls a parallel trans-acting step for Bcl11b activation.   BM-
derived DN2 progenitors with different Bcl11b allelic activation states were sorted, cultured on 
either OP9 (-Notch) or OP9-DL1 (+Notch) monolayers for four days, and analyzed using flow 
cytometry.  A) Flow cytometry plots show Bcl11b-mCherry versus Bcl11b-YFP expression 
levels in analyzed cells.  Percentages of non-expressing, monoallelic expressing  (both YFP and 
mCherry) and biallelic expressing cells were used to calculate the locations in the phase space.  
Note that when Notch signaling is withdrawn from biallelically expressing cells, they 
downregulate both alleles coordinately (green shaded arrow). B) Phase space diagrams 
experimentally obtained from analysis of flow cytometry data. Points in phase space represent 
the average of 2-4 replicate data points in a single experiment (hollow circles).  Inset shows final 
activation states of bi-allelic starting progenitors upon Notch withdrawal.  Results shown are 
representative of 3 independent experiments.  C)-D) Predicted phase space diagrams for fraction 
of biallelic expressing cells (Fb) against the fraction of monoallelic expressing cells (Fm, YFP+ 
and mCh+ combined), for either the sequential trans-cis activation model (C), or the parallel 
trans-cis model (see Mathematical Appendix for details).  Black (colored) dotted lines connect 
initial state to the normal (perturbed) final state.  Note that actual developmental trajectories may 
be curved (not shown).  Arrows show predicted shifts in final state due to the indicated 
perturbations.  Note that perturbations affect both the rates and reversibility of the indicated 
reactions.  See also Figure S7.  
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Figure 6:  Probabilistic Bcl11b activation occurs within a limited developmental time window. 
Cells expressing only one Bcl11b allele at the indicated stages were sorted from thymocytes, 
cultured for 4d on OP9-DL1 monolayers, and analyzed for activation of the initially inactive 
Bcl11b allele using flow cytometry.  A) Flow plots (left) show Bcl11b-mCh versus Bcl11b-YFP 
expression levels for descendants of cells that had monoallelic expression at the indicated stages 
of development; bar charts (right) show the fraction of progenitors from different stages that 
activate the silent Bcl11b allele upon culture.  Data represent mean and standard deviation of 4-5 
replicates, derived from 2 independent experiments.  The competence to activate the silent 
Bcl11b allele decreases upon progression to the DN3 stage and beyond.  B) Flow plots (left) 
show Bcl11b-mCh versus Bcl11b-YFP expression levels for DN2 or DN3 progenitors with either 
an intact YFP allele enhancer (top) or a disrupted YFP allele enhancer (bottom).  Bar chart 
(right) shows the fraction of cells activating the silent Bcl11b allele upon re-culture.  Data show 
that enhancer disruption reduces the Bcl11b activation advantage in DN2 cells as compared to 
DN3 cells.  Data represent mean and standard deviation of 3 replicates from 2 independent 
experiments.  	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Figure 7.  Model of Bcl11b regulation by parallel cis and trans limiting steps.  Bcl11b activation 
requires two rate-limiting steps: a switch of the Bcl11b locus from an inactive to active 
epigenetic state, and the activation of a trans factor is necessary for transcription of Bcl11b from 
an activated locus.  Notch signaling activates TCF-1 and GATA3 in early thymic progenitors  
(García-Ojeda et al., 2013; Scripture-Adams et al., 2014; Weber et al.), and these two factors 
may act on the identified distal enhancer to control the rate-limiting cis step on the Bcl11b locus 
(green).  In parallel, Notch promotes the activation of a trans factor (red) that is necessary for 
transcription from a cis-activated Bcl11b locus.  The cis and trans limiting steps together control 
the dynamics of Bcl11b expression and T-cell lineage commitment. 
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Figure S1:  Experimental strategy for generating different Bcl11b reporter mouse strains, Related 
to Figures 1 and 3. The two Bcl11b loci were targeted in embryonic stem (ES) cells using 
homologous recombination, followed by drug selection using the indicated drug-resistance 
markers (vertical arrows).  ES cells were then injected into blastocysts (horizontal arrows) to 
generate the indicated mice.  These mice were subsequently bred to generate the appropriate 
two-color mice for experiments (see Methods). To generate the enhancer disrupted ES cells, the 
dual-color tagged ES line was retargeted with a deletion construct including a selectable 
hygromycin resistance gene (hyg). Cells with the correct insertion were then used to generate 
mice.  
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Figure S2:  Bcl11b shows heterogeneity in locus activation within clonal progenitor lineages, 
Related to Figures 2 and 4.  Bone marrow derived Bcl11b-YFP-mCherry- DN2 progenitors were 
sorted, seeded on OP9-DL1 monolayers within PDMS micro-well arrays, and continuously 
observed using long-term timelapse imaging.  Microwells seeded with single proliferating cell 
clones were identified, and Bcl11b activation states of descendants were then analyzed after four 
days.  A) Timelapse images show DIC (gray), YFP (yellow) and mCherry (red) fluorescence of 
cells descended from single progenitors.  Each row represents cells within a single microwell.  
Images were taken between 105 and 115 hours after onset of imaging.  Scale bar represents 10 
microns.  B) Stacked bar chart shows the range of Bcl11b activation states observed for clonal 
descendants after four days.  Left bar indicates clones where cells were all found in the same 
activation state; right bar gives clones with multiple activation states observed within a single 
clone. 
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Figure S3.  Levels of monoallelic Bcl11b expression in thymus subsets: monoallelic expression 
can persist throughout thymic development, Related to Figure 3.  A) Representative flow 
cytometry plots showing gating strategies for thymic subsets and two-color Bcl11b expression in 
these populations from Bcl11bYFP/mCh(neo) (wildtype) or Bcl11bYFPΔEnh/mCh(neo) (Δenhancer) mice.  
DN subsets were enriched by magnetic bead depletion of mature thymic cells before staining and 
analysis. B)  Percentages of cells expressing only mCherry (RFP mono) or YFP (YFP mono) in 
specific T cell populations from Bcl11bYFP/mCh(neo) (wt) or Bcl11bYFPΔEnh/mCh(neo) (YFPΔenh) 
mice. Each symbol represents results from an individual mouse (n=4 to 6 mice per group). This 
figure shows that although biallelic expression predominates, monoallelic expression of both 
YFP and mCherry wildtype alleles persist in some cells throughout intrathymic development. 
Furthermore, the YFPΔenh mutant dramatically increases the percentage of cells expressing only 
the mCherry (wildtype) allele due to failure to activate the mutant allele. However, the level of 
monoallelic expression seen decreases generally over development of CD4 and CD8 SP αβ T 
cells and is slightly higher among TCRγδ+ and NKT cells relative to conventional TCRβ+ cells, 
possibly consistent with additional selection events. 
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Figure S4.  Monoallelic Bcl11b expression persists in peripheral splenic T-cell subsets and is cell 
autonomous.  Related to Figure 3.  A) Representative flow cytometry plots showing gating 
strategies for splenic subsets and two-color Bcl11b expression in these populations from 
Bcl11bYFP/mCh(neo) (wildtype) or Bcl11bYFPΔEnh/mCh(neo) (Enhancer deleted) mice.  Some T-cell 
subsets were enriched by magnetic bead depletion of B cells before staining and analysis as 
indicated. B) Percentages of cells expressing only mCherry (RFP mono) or YFP (YFP mono) in 
specific T cell populations from Bcl11bYFP/mCh(neo (wt) or Bcl11bYFPΔEnh/mCh(neo) (YFPΔEnh) 
mice. Each symbol represents results from an individual mouse (n=2 to 8 mice per group). The 
data show that patterns of monoallelic expression seen in the thymus (cf. Figure S3) persist in the 
periphery in CD4, CD8 NKT, and TCRγδ T cells, for both wildtype and YFPΔenh mutant 
alleles. However, there are subset differences which are most evident in the mCherry 
wildtype/YFP Δenh genotype. In particular, activated or antigen-experienced (CD44+) CD8 cells 
show a greater frequency of monoallelic mCherry expression than naïve (CD44-) CD8 cells, 
whereas CD4+ CD25+ Treg cells exhibit much lower levels of monoallelism than conventional 
CD4+ and CD8+ cells. These results could be related to the specific requirements for Bcl11b 
activity in different peripheral T-cell subsets (Avram and Califano, 2014).   C)-D) Cell autonomy 
of Bcl11b expression control in hematopoietic chimeric mice. B6.Cd45.1 mice were irradiated 
with 1000 rads and injected retro-orbitally with 106 fetal liver cells from Bcl11bYFP/mCh(neo) (wt) 
and Bcl11bYFPΔEnh/mCh(neo) (YFPΔEnh) (Cd45.2+) mice (F0 generation).  After 8 weeks chimeric 
mice were analyzed for expression of the wild type (wt) mCherry and wt or mutant (ΔEnh) YFP 
alleles. C) Representative flow cytometry plots showing gating strategies for CD45.2+ splenic 
subsets and two-color Bcl11b expression in these populations from Bcl11b. Other thymic and 
splenic T-cell populations were gated similarly to those shown Figures S3 and S4. D) 
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Percentages of cells expressing only mCherry (RFP mono) or YFP (YFP mono) in specific T cell 
populations, demonstrating the persistence of small but similar percentages of monoallelically 
expressed mCherry and YFP alleles in wt mice and the major increase in monoallelic mCherry 
positive cells in the presence of the YFPΔEnh mutant alllele.  Each symbol represents results 
from an individual mouse (n=2 mice per group). Results are shown for chimeras from one 
wildtype/mutant F0 donor pair. Similar results were obtained from chimeras from a different pair 
of wildtype and mutant fetal F0 donors. 
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Figure S5: Thymocytes from homozygous mutant enhancer mice Bcl11bYFPΔEnh/YFPΔEnh mice are 
able to generate T-cell subsets expressing Bcl11b at normal levels relative to wild type enhancer 
Bcl11b YFP/ YFP mice, Related to Figure 3. Representative FACS plots showing gates used for 
CD4 and CD8 double negative (DN), double positive (DP) and single positive (CD4 and CD8) 
populations (left plots) and the relative levels of Bcl11b-YFP in each subset generated from 
enhancer mutant and wild type mice (right histograms,  n=2 for each genotype). 
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Figure S6:  Clones show mono-allelic expression from a single allele during Bcl11b activation.  
A) Table shows observed numbers of clones with indicated allelic activation patterns, showing 
data from three independent experiments.  Simulations of clonal lineages from sequential or 
parallel trans-cis activation models are shown (N=30,000 simulations).  See Figure 4 and main 
text for model description and allelic pattern definition.  B) Live images show cells from two 
clonal lineages showing a single mono-allelic pattern of activation, with mono-allelic expression 
of either the red allele only (Clone I), or the yellow allele only (Clone II).  Images shown are 
from Experiment 3, whereas images and data in Fig. 4 are shown from Experiment 1. 
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Fig. S7. Notch controls a parallel trans-acting step for Bcl11b activation, Related to Figure 5. 
The  parallel and sequential trans-cis Bcl11b activation models (upper and lower panels, 
respectively). Effects of perturbation of cis (blue) or trans (green) acting steps in both models are 
shown with colored arrows. Phase space diagrams show the predicted final fractions of mono-
allelic expressing cells (FM, sum of mono-allelic cells from both alleles), and bi-allelic expressin 
cells (Fb), for both unperturbed cells (black lines) and cells where the indicated reaction steps are 
perturbed (colored lines).  Definitions for the forward and back rate constants (kf0, kf1, kr0, kr1) 
are given in Tables 3-6 of the Mathematical Appendix.   
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METHODS  
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by Lead Contact, Ellen Rothenberg (evroth@its.caltech.edu)  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Animals 
Fo chimeric mice from Bcl11bYFP/mCh(neo) and Bcl11bYFPΔEnh/mCh(neo) ES-cell blastocyst 
injections were all made in our lab (described in Method Details). Founder animals were brought 
to term and crossed in house to generate Bcl11bYFP(neo)/mCh(neo), Bcl11bYFP/mCh(neo), 
Bcl11bYFPΔEnh/mCh(neo), and Bcl11bYFPΔEnh/mCh(neo) mice. CD45.1 C57BL/6 mice were purchased 
from Jackson Laboratory. All adult animals were used between 5 and 12 weeks of age. Both 
male and female mice were used similarly in all studies. Animals were bred and maintained in 
the Caltech Laboratory Animal Facility, and animal protocols were reviewed and approved by 
the Institute Animal Care and Use Committee of the California Institute of Technology.  
 
Cells 
Primary cells isolated from thymus, spleen, bone marrow, and fetal livers were cultured on a 
OP9-DL1 stromal monolayer system (Schmitt and Zúñiga-Pflücker, 2002) at 37oC in 5% CO2 
conditions with standard culture medium [80% αMEM (Gibco), 20% Fetal Bovine Serum 
(Sigma-Aldrich), Pen-Strep-Glutamine (Gibco), 50 µM β-mercaptoethanol (Sigma)] 
supplemented with appropriate cytokines (described in Method Details).  
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METHOD DETAILS 
Construct Designs  
  Gene targeting vectors for generating dual allelic Bcl11b fluorescent reporter and 
subsequent enhancer knockout were constructed using a two-step bacterial artificial chromosome 
(BAC) recombineering method. First, Bcl11b-BACs were modified to either insert a fluorescent 
reporter or disrupt the enhancer sequence with a drug selection marker. An internal ribosome 
entry site (IRES)-histone 2B-mCherry red fluorescent protein (mCh)-loxP-neomycin (neo)-loxP 
cassette with homology arms targeting the 3’-untranslated region (UTR) of Bcl11b was derived 
from a similar histone 2B-mCitrine yellow fluorescent protein (YFP) gene targeting vector 
version published previously (Kueh et al., 2016) and an IRES-H2B-mCherry-loxP-neomycin 
(neo)-loxP cassette. These two starting plasmids were digested with restriction enzymes NheI 
and HindIII (New England Biolabs) to exchange the fluorescent protein sequences. Homology 
arms flanking the 5’ and 3’ ends of the 1.9kb enhancer (Enh) sequence to be replaced (chr12: 
108,396,825-108,398,612, mm9 assembly; chr12:107,158,615-107,160,462, in mm10) were 
attached to a FRT-PGK-gb2-hygromycin (hygro)-FRT drug selection cassette through fusion 
PCR, and inserted into a cloning vector (pGEM-T-Easy, Promega). Next, restriction enzymes 
were used to release the homology-flanked fluorescent or drug reporter cassettes, and the 
resultant linear fragments were introduced into recombineering E. Coli strain SW102 containing 
appropriate BACs for specific targeting. The IRES-mCh-neo fragment was linearized with AatII, 
SalI-HF, ScaI-HF and knocked into a BAC containing the entire Bcl11b gene locus (RP24-
282D6, from http://bacpac.chori.org). Restriction enyzmes XmnI, PspOMi, and SbfI released the 
FRT-hygro-FRT cassette used to replace the enhancer sequence in a BAC containing genomic 
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regions downstream of the Bcl11b locus (RP23-445J15, from http://bacpac.chori.org). Correctly 
modified BACs were then selected using kanamycin or hygromycin in combination with 
chloramphenicol, and verified by PCR and pulse-field gel electrophoresis analysis using the 
restriction enzyme NotI (New England Biolabs).  
 A second recombineering reaction retrieved the targeting sequences from reporter 
modified Bcl11b-BACs. The retrieval vector used to fetch the targeting sequence from the 
modified Bcl11b-mCherry-neo BAC was made in a previous study (Kueh et al., 2016). For 
retrieval of the enhancer-disrupted sequence, homology arms for retrieval were first generated 
using fusion PCR, then cloned into a vector containing a Herpes Simplex Virus-Thymidine 
Kinase (HSV-TK) cassette using restriction enzymes NotI and SpeI (New England Biolabs). 
Both retrieval vectors were linearized with PacI and AscI (New England Biolabs), introduced 
into SW102 containing respective modified Bcl11b-BACs, and retrieved targeting sequences 
between the homologous ends to generate the desired gene targeting vectors. Clones that 
underwent correct retrieval reactions were selected using kanamycin or hygromycin in 
combination with ampicillin, and verified with restriction enzyme digests and sequencing.  
 The retroviral construct expressing IRES-H2B-mCerulean cyan fluorescent protein (CFP) 
used for timelapse imaging experiments was generated in a previous study (Kueh et al., 2013).  
A complete list of vectors used is provided in Key Resources Table. 
 
Mouse Generation  
A series of genetic modifications were performed to generate different Bcl11b reporter 
mouse strains used for this study (Figure S1). V6.5 mouse embryonic stem (ES) cells with a 
single modified Bcl11b allele expressing the IRES-H2B-mCitrine-loxp-neo-loxp fluorescent 
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reporter were first transfected with Cre recombinase to excise the neomycin cassette.  Subclones 
of this line with a correct deletion of the neomycin cassette were then targeted with the IRES-
mCherry-neo gene targeting vector to generate dual allelic Bcl11b fluorescent reporter cells, and 
targeted again with the ΔEnh-hygro cassette to delete the enhancer in one allele. After each 
targeting event, recombinant ES cells grown on feeders were positively selected with antibiotics 
according to the cassette inserted, and negatively selected with G418. Resistant clones were 
passaged onto feeder-free conditions and screened using PCR and qPCR for correct targeting. 
Clones with the desired genotype were karyotyped for normal chromosome numbers before 
being injected into C57BL/6 blastocyst embryos or subjected to subsequent gene targeting. 
F0 chimeric mice from Bcl11bYFP/mCh(neo) and Bcl11bYFPΔEnh/mCh(neo) ES-cell blastocyst 
injections were generated, and either analyzed at embryonic day 14.5 (E14.5) or brought to term 
for breeding. Bcl11bYFP/mCh(neo) F0 chimeric mice were crossed to C57BL/6 mice, and the 
offspring containing Bcl11b-IRES-mCherry-neo allele were then bred to homozygosity for this 
allele. Dual allelic Bcl11bYFP(neo)/mCh(neo) mice with identical Bcl11b alleles except for fluorescent 
protein reporters were generated from breeding Bcl11bmCh(neo)/mCh(neo) mice to previously 
produced Bcl11bYFP(neo)/YFP(neo) mice (Kueh et al., 2016), and were used for in vitro assay studies 
of bone marrow derived T-cells.  Bcl11bYFPΔEnh/mCh(neo) mice were generated in a similar manner 
by first breeding to C57BL/6 mice to generate enhancer deleted heterozygotes, then crossing 
mice to Bcl11bmCh(neo)/mCh(neo). Bcl11bYFPΔEnh/YFPΔEnh mice were generated in parallel by crossing 
enhancer deleted heterozygotes together. For experiments comparing the effects of the enhancer 
on Bcl11b expression, direct control Bcl11bYFP/mCh(neo) mice were generated from breeding 
Bcl11bYFP/YFP and Bcl11bmCh(neo)/mCh(neo) animals. However, we have previously reported that the 
presence or absence of neo cassette does not affect the Bcl11b reporter locus (Kueh et al., 2016), 
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and do not observe any differences in expression pattern in this study as well (see Figures 1 and 
3).    
 
Cell Purification  
Thymocytes and splenocytes were purified from lymphoid organs removed from 4- to 6- 
week old normal and enhancer-deleted two-color Bcl11b reporter strains, and 2-month post fetal 
liver precursor transplantation CD45.1 chimeras prior to flow cytometry analysis or fluorescent 
activated cell sorting (FACS). Harvested lymphoid organs were mechanically dissociated to 
make single cell suspensions that were re-suspended in Fc blocking solution with 2.4G2 
hybridoma supernatant (prepared in the Rothenberg lab). Early stage thymocyte precursors to be 
analyzed (ETP, DN2a, DN2b, DN3: Figures 1C, 3B, and S3) or sorted (DN2, DN3: Figures 3D 
and 6A), were first depleted of mature cell lineages using a biotin-streptavidin-magnetic bead 
removal method. Thymocyte suspensions were labeled with biotinylated lineage marker 
antibodies (CD8α, TCRβ, TCRγδ, Ter119, Gr-1, CD11c, CD11b, NK1.1), incubated with 
MACS Streptavidin Microbeads (Miltenyi, Biotec) in HBH buffer (HBSS (Gibco), 0.5% BSA 
(Sigma-Aldrich), 10 mM HEPES, (Gibco)) pre-filtered through cell separation magnet (BD 
Biosciences), and passed through a magnetic column (Miltenyi Biotec). Rare T-cell subsets 
found in the spleen (Figures S4) were enriched using a similar depletion protocol by labeling 
splenocytes with biotinylated antibodies CD19, CD11b, CD11c, and Gr-1. Later-stage thymocyte 
precursors analyzed (Figures 1C, 3B, S3, and S5) or sorted (Figures 6A), and whole splenocyte 
populations analyzed (Figures S4 and S5) were directly stained with conjugated fluorescent cell 
surface antibodies (see Table S1, Key Resources Table).  
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/318675doi: bioRxiv preprint first posted online May. 10, 2018; 
43	  	  
Bone Marrow (BM) cells were harvested from dissected femurs and tibiae of 2- to 3- 
month-old Bcl11bYFP(neo)/mCh(neo) mice. Fetal livers (FLs) were removed from F0 chimeric fetuses 
of pregnant surrogate mice at E14.5, individually disrupted mechanically via pipetting into whole 
organ suspension, and frozen down in freezing media (50% FBS, 40% αMEM, 10% DMSO) for 
liquid nitrogen storage. Prior to in vitro culture use, BM and thawed FL cell suspensions were 
blocked in 2.4G2 supernatant, tagged with biotinylated antibody lineage markers specific to BM 
(CD19, CD11b, CD11c, NK1.1, Ter119, CD3ε, Gr-1, B220) or FL (CD19, F4/80, CD11c, 
NK1.1, Ter119, Gr-1), and depleted of biotin-streptavidin-magnetically labeled mature lineage 
cells as described above. Eluted lineage depleted (Lin-) bone marrow progenitors were either 
frozen down in freezing media for storage in liquid nitrogen or used directly for in vitro cell 
culture assays of T-cell development, while Lin- fetal liver progenitors were immediately 
cultured.  
 
In vitro Differentiation of T-cell Progenitors 
DN T cell precursors used for in vitro studies were generated by culturing BM and FL 
stem and progenitor cells on a OP9-DL1 stromal monolayer culture system (Schmitt and Zúñiga-
Pflücker, 2002), following previously detailed methods (Kueh et al., 2016) with adapted 
variations as described below. To promote the DN T cell development, purified or thawed Lin- 
progenitors were cultured on OP9-DL1-GFP stromal cell monolayers (Schmitt and Zúñiga-
Pflücker, 2002) plated on tissue-culture treated plates (Corning) using standard culture medium 
[80% αMEM (Gibco), 20% Fetal Bovine Serum (Sigma-Aldrich), Pen-Strep-Glutamine (Gibco), 
50 µM β-mercaptoethanol (Sigma)], grown at 37oC in 5% CO2 conditions, and supplemented 
with cytokines. All in vitro T-cell generation cultures of Bcl11b-YFP/mCh Lin- BM precursors 
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were supplemented with 5 ng/mL Flt-3L (Peprotech) and 5 ng/mL IL-7 (Peprotech), and were 
sorted after 6 or 7 total days of culture following transduction with a retroviral vector expressing 
CFP 1 day prior (Figures 2, 4F, 5B, and S2). Lin- fetal liver precursors were cultured with 5 
ng/mL Flt-3L and 1 ng/mL IL-7 for the indicated number of days before analysis or sorting.  
Sorted thymocytes (Figures 3D and 6A), BM-derived DN2 progenitors (Figure 5B), and 
FL-DN progenitors (Figure 6B) were seeded manually onto 6000 OP9-DL1-GFP or OP9-Mig 
feeder cells per well in 96-well plates, cultured in standard medium supplemented with 5 ng/mL 
Flt-3L and either 5 ng/mL IL-7 (BM) or 1 ng/mL IL-7 (Thymocytes and FL), and harvested for 
analysis after the indicated number of days.  
 
Flow Cytometry and Cell Sorting 
Unless otherwise noted, flow cytometry analysis and fluorescent activated cell sorting of 
all in vitro and ex vivo lymphocytes were prepared using the procedures outlined. Briefly, 
cultured cells on tissue culture plates and primary cells from lymphoid organs were prepared as 
single cell suspensions, incubated in 2.4G2 Fc blocking solution, stained with respective surface 
cell markers as indicated (see Table S1, Key Resources Table), resuspended in HBH, filtered 
through a 40-µm nylon mesh, and analyzed using a benchtop MacsQuant VYB flow cytometer 
(Miltenyi Biotec, Auburn, CA) or sorted with Sony Synergy Sorter (Sony Biotechnology, Inc, 
San Jose, CA). Both instruments contain capabilities to detect mCherry fluorescence by 561-nm 
laser excitation. All antibodies used in these experiments are standard, commercially available 
monoclonal reagents widely established to characterize immune cell populations in the mouse; 
details are given in Table S1. Acquired flow cytometry data were all analyzed with FlowJo 
software (Tree Star). 
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Timelapse Imaging 
Timelapse imaging of live-cells was used to study Bcl11b gene expression dynamics in 
single cells (Figures 2, 5F, S2, and Movie S1). To prepare for multi-day imaging, PDMS 
micromesh arrays (250-µm hole diameter, Microsurfaces, AU) containing small microwells that 
prevent seeded cells from migrating out of a single imaging field of view on 40x objective were 
adhered to 24 well glass-bottomed plates (Mattek, Ashland, MA). To prevent overcrowding in 
microwells and enable proper cell tracking, non-GFP expressing OP9-DL1-hCD8 cells (1) and 
sorted CFP+ DN2 progenitors were plated at appropriate densities to achieve ~8 cells/microwell 
and ~1 cell/microwell, respectively. Cells were cultured in standard medium using Phenol Red-
free αMEM (Gibco) and supplemented with 5 ng/mL Flt-3L and 5 ng/mL IL-7. 
 
Image segmentation and analysis 
Cells were segmented using image processing workflow implemented in MATLAB 
(Mathworks, Natick, MA), as previously described in detail (Kueh et al., 2013, 2016).  Briefly, 
this workflow involved:  1) Correction for uneven fluorescence illumination, calculated from a 
fluorescent slide with uniform intensity, followed by background subtraction; 2) Automated cell 
segmentation, using an Laplacian filter-based edge detection algorithm, followed by exclusion of 
non cell objects by size and shape selection.  Cell segmentations were then subject to manual 
inspection, and segmented objects that did not correspond to cells were then eliminated.  For 
each data set, automated segmentation parameters were chosen such that the fraction of 
incorrectly identified cells was <1% of the total number of segmented cells.  To calculate 
fluorescence intensities for segmented cells, we first calculated average intensity levels for an 
annulus surrounding the segmented cell, and subtracted this background value from image 
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intensities in the cell interior.  This additional subtraction was performed to remove auto-
fluorescence contributions from OP9-DL1 feeder cells to intensity measurements.  Fluorescence 
intensity measurements were either displayed for clonal cell lineages confined within individual 
microwells (Figures 2B and S2A), or in a two-dimensional heat map showing the intensity 
distributions for different indicated time windows for all 218 microwells in a single imaging 
experiment.  To obtain the time evolution of Bcl11b population fractions, a least-squares fit of a 
four-component mixed 2D Gaussian was performed on Bcl11b intensity distributions for 
successive time windows, with each component corresponding to a distinct cellular state (Bcl11b 
YFP-mCh-, YFP+mCh-, YFP-mCh+, YFP+mCh+).  The relative abundance of each state was then 
estimated using the area under each best-fit curve (Figure 2D).  This approach was used to 
provide an unbiased estimate of population sizes that did not depend on manually defined 
thresholds. 
 
Model analysis and fitting 
Models for Bcl11b activation (Models I-III; Figure 4B, Mathematical Appendix) were 
numerically simulated using an ordinary differential equation solver in MATLAB.  The 
predicted time course from these models were fit to experimental data, using a least-squares 
procedure with the following free parameters:  the cis- and trans- activation rates (kC and kT 
respectively), and the fraction of cells in each Bcl11b non-expressing sub-state, constrained to 
equal one at t = 0 (sequential and parallel trans-cis models only).  Best fits of the different 
models were then evaluated by comparing sum-squared errors using the F-test, adjusted for 
different degrees of freedom for each model.  Qualitative predictions for perturbing specific 
reaction steps (Figure S7) were obtained by performing a series of simulations with increasing 
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magnitude of perturbation to the same ending time point.  In accordance with experimental 
observations showing some inactivation of the Bcl11b locus upon Notch withdrawal (Figures 
5B-C), perturbations involved both a reduction of the forward rate constant, and an increase in 
the rate of a reverse reaction, together with a graded attenuation in the perturbation after 
activation of one Bcl11b allele (see Figure S7, and Mathematical Appendix for a comprehensive 
description).  Parameters were chosen based on the best fits of the unperturbed time course 
(Figure 4C), though the direction of the predicted shifts in phase space do not depend on the 
exact parameters being chosen (Figure 5A). 
To generate predictions for allelic state distributions from single clones (Figures 5E-F), 
we performed Monte-Carlo simulations of clonal single proliferating progenitor lineages, using 
Markov transition probabilities determined by best-fit rate constants to Models II or III (see 
Mathematical Appendix).  Here, the cell division time was taken to be 20 hrs, corresponding to 
rates of cell expansion observed in experiments, and measurements of clonal allelic distributions 
were taken at 100 hrs (i.e. after 5 cell divisions), also matching the time of experimental 
sampling.  Probabilities per cell division for each transition were obtained by converting the 
continuous-time models to a discrete Markov chain, and these probabilities were taken to be 
independent between two daughters of the same cell, consistent with the first-order kinetics of 
these transitions in our models.  To test experimental data against each model, we obtained the 
expected probability of having clones with dual-allelic expression together with monoallelic 
expression from two alleles (Y+R+D) or from a single allele (Y+D and R+D) clones, for each 
model, and compared the observed frequencies from clonal lineage data using a chi-squared test. 
 
Radiation Chimeras  
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/318675doi: bioRxiv preprint first posted online May. 10, 2018; 
48	  	  
Fetal liver precursor transplanted CD45.1 chimeras were generated to study the long-term 
T-cell potential of cells without Bcl11b enhancer in mice. Individual fetal liver whole organ 
suspensions were thawed and split for depletion protocols indicated above or stimulated in 
standard medium supplemented with 50 ng/mL IL-6 (eBioscience), 50 ng/mL SCF 
(eBioscience), and 20 ng/mL IL-3 (eBioscience) for 2 days to enrich for hematopoietic stem cell 
(HSC) progenitors. CD45.1 C57BL/6 mice were subjected to sublethal radiation of 1000 rads 
from a cesium source. Cells were re-suspended in PBS and 106 cells in a volume of 200 µL were 
injected retro-orbitally into anesthesized, irradiated mice using 31G, 6 mm insulin syringes (BD). 
Comprehensive splenocyte analysis was performed on 2-month post transplantation chimeras by 
sacrificing mice and harvesting spleen and thymus organs following protocols indicated above 
(Figure S5).  
 
Retroviral Transduction on Retronectin-DL1 Coated Plates  
Retroviral particles were packaged by transient cotransfection of the Phoenix-Eco 
packaging cell line with the retroviral construct and the pCL-Eco plasmid (Imgenex) using 
FuGENE 6 (Promega). Viral supernatants were collected at 2- and 3-days after transfection and 
immediately frozen at -80oC until use. To infect BM-derived T-cell progenitors, 33 µg/mL 
retronectin (Clontech) and 2.67 µg/mL of DL1-extracellular domain fused to human IgG1 Fc 
protein (Varnum-Finney et al., 2000) were added in a volume of 500 µL per well in 24-well 
tissue culture plates (Costar, Corning) and incubated overnight. Viral supernatants were added 
next day into coated wells and spun down at 2000 rcf for 2 hours at room temperature. BM-
derived T-cell progenitors used for viral transduction were cultured for 5 days according to 
conditions described above, disaggregated, filtered through a 40-µm nylon mesh, and 106 cells 
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transferred onto each retronectin/DL1-coated virus-bound 24-well supplemented with 5 ng/mL 
SCF (Peprotech), 5 ng/mL Flt3-L, and 5 ng/mL IL-7.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
The sample size for each experiment, and number of independent experiments are stated 
in the Figures and Figure Legends. In Figure 4C, the best fits of the different models were 
evaluated by comparing sum-squared errors using the F-test (Figure 4D), adjusted for different 
degrees of freedom for each model. A chi-squared test was applied to compare experimental data 
against model predictions shown in Figure 4F. Data that had a calculated P-value <0.05 was 
considered statistical significant, and exact P-values are reported in the figure legends.  Bar chart 
data shown (Figures 6A-B) represent mean and standard deviation.  
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Table S1: List of Antibodies.   
Antibody Usage 
Anti-mouse CD8α Biotin 
(clone 53-6.7) 
Thymic DP and SP depletion. Figure 6A (Thymic DNs analysis), Figure 6B 
(FL DNs analysis) 
Anti-mouse TCRβ Biotin 
(clone H57-597) 
Thymic DP and SP depletion 
Anti-mouse TCRγδ Biotin 
(clone GL3) 
Thymic DP and SP depletion  
Anti-mouse Ter119 Biotin 
(clone TER-119) 
Thymic DP and SP depletion, Bone marrow depletion, Fetal liver depletion. 
Figure 2 (BM-derived DNs sort) 
Anti-mouse NK1.1 Biotin 
(clone PK136) 
Thymic DP and SP depletion, Bone marrow depletion, Fetal liver depletion. 
Figure 2 (BM-derived DNs sort) 
Anti-mouse Gr-1 Biotin 
(clone RB6-8C5) 
Thymic DP and SP depletion, Bone marrow depletion, Fetal liver depletion, 
Splenocyte depletion. Figure 2 (BM-derived DNs sort) 
Anti-mouse CD11c Biotin 
(clone N418) 
Thymic DP and SP depletion, Bone marrow depletion, Fetal liver depletion, 
Splenocyte depletion. Figure 2 (BM-derived DNs sort) 
Anti-mouse CD11b Biotin 
(clone M1/70) 
Thymic DP and SP depletion, Bone marrow depletion, Splenocyte depletion. 
Figure 2 (BM-derived DNs sort) 
Anti-mouse CD19 Biotin 
(clone 1D3/6D5) 
Bone marrow depletion, Fetal liver depletion, Splenocyte depletion. Figure 2 
(BM-derived DNs sort) 
Anti-mouse CD3ε Biotin 
(clone 145-2C11) 
Bone marrow depletion. Figure 2 (BM-derived DNs sort), Figure S3 (Total 
Thymocytes analysis)  
Anti-human/mouse B220 
Biotin (clone RA3-6B2) 
Bone marrow depletion 
Anti-mouse F4/80 Biotin 
(clone BM8) 
Fetal liver depletion  
Anti-mouse CD4 Biotin 
(clone GK1.5) 
Figure 6A (Thymocyte DNs analysis), Figure 6B (FL DNs analysis) 
Anti-human/mouse CD44 
eFluor 450 (clone IM7) 
Figure 1C (ETP-DN3, CD4/CD8 analysis), Figure 3B (ETP-DN3 analysis), 
Figure 3D (Thymocyte DNs sort and analysis), Figure 6A (Thymocyte DNs 
sort and analysis), Figure 6B (FL DNs sort and analysis), Figure S3 (Depleted 
Thymocytes analysis), Figure S4A-B (Depleted Splenocytes analysis), Figure 
S4C-D (Total Splenocytes analysis) 
Anti-mouse CD25 Brilliant 
Violet 510 (clone PC61) 
Figure 1C (ETP-DN3 analysis), Figure 3B (ETP-DN3 analysis), Figure 3D 
(analysis), Figure 6B (FL DNs sort), Figure S3 (Depleted Thymocytes 
analysis) 
Anti-mouse CD117 (cKit) 
APC-eFluor 780 (clone 
2B8) 
Figure 1C (ETP-DN3 analysis), Figure 3B (ETP-DN3 analysis), Figure S3 
(Depleted Thymocytes analysis) 
Anti-mouse HSA eFluor 
450 (clone M1/69) 
Figure 1C (DP analysis), Figure 3B (DP analysis), Figure 6A (Total 
Thymocytes sort and analysis), Figure S3 (Total Thymocytes analysis) 
Anti-mouse CD4 Brilliant 
Violet 510 (clone GK1.5) 
Figure 1C (DP, CD4/CD8 analysis), Figure 3B (DP, CD4/CD8 analysis), 
Figure 6A (Total Thymocytes sort and analysis), Figure S3 (Total Thymocytes 
analysis), Figure S4A-B (Total and Depleted Splenocytes analysis) 
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Anti-mouse CD8α APC 
(clone 53-6.7) 
Figure 1C (DP, CD4/CD8 analysis), Figure 3B (DP, CD4/CD8 analysis), 
Figure 6A (Total Thymocytes sort and analysis), Figure S3 (Total Thymocytes 
analysis), Figure S4A-B (Total Splenocytes analysis), Figure S4C-D (Total 
Thymocytes and Splenocytes analysis), Figure S5 (Total Thymocytes analysis) 
Anti-mouse TCRβ APC-
eFluor 780 (clone H57-597) 
Figure 6A (Total Thymocytes sort), Figure S3 (Total Thymocytes analysis) 
Anti-mouse CD25 APC-
eFluor 780 (clone PC61.5) 
Figure 1C (DP, CD4/CD8 analysis), Figure 2 (BM-derived DNs sort), Figure 
3B (DP, CD4/CD8 analysis), Figure 3D (Thymocyte DNs sort), Figure 5A 
(BM-derived DNs analysis), Figure 6A (Thymocyte DNs sort), Figure 6B (FL 
DNs analysis), Figure S3 (Total Thymocytes analysis), Figure S4 (Total 
Splenocytes analysis) 
Anti-mouse CD19 eFluor 
450 (clone 1D3/6D5) 
Figure S4 (Total Splenocytes analysis) 
Anti-mouse CD117 (cKit) 
APC (clone 2B8) 
Figure 3D (Thymocyte DNs sort), Figure 6A (Thymocyte DNs sort) 
Anti-mouse CD45 APC-
eFluor 780 (clone 30-F11) 
Figure 3D (Thymocyte DNs analysis), Figure 6A (Thymocyte DNs, DP, 
CD4SP analysis) 
Anti-mouse CD25 APC 
(clone PC61.5) 
Figure 6A (Thymocyte DNs analysis) 
Anti-mouse CD4 APC-
eFluor 780 (clone GK1.5) 
Figure 6B (FL DNs sort), Figure S4C-D (Total Thymocytes and Splenocytes 
analysis) 
Anti-mouse CD8α APC-
eFluor 780 (clone 53-6.7) 
Figure 6B (FL DNs sort), Figure S4 (Depleted Splenocytes analysis), Figure 
S7 (Total Splenocytes analysis) 
Anti-mouse CD45 PerCP-
Cyanine5.5 (clone 30-F11) 
Figure 6B (FL DNs sort) 
Anti-mouse CD45 APC 
(clone 30-F11) 
Figure 6B (FL DNs analysis) 
Anti-mouse CD5 eFluor 
450 (clone 53-7.3) 
Figure S3 (Total Thymocytes analysis) 
Anti-mouse TCRγδ APC 
(clone GL3) 
Figure S3 (Total Thymocytes analysis), Figure S4A-B (Depleted Splenocytes 
analysis), Figure S4C-D (Total Thymocytes and Splenocytes analysis) 
Anti-mouse CD49b eFluor 
450 (clone DX5) 
Figure S3 (Total Thymocytes analysis) 
Anti-mouse NK1.1 APC 
(clone PK136) 
Figure S3 (Total Thymocytes analysis), Figure S4 (Depleted Splenocytes 
analysis) 
Anti-mouse CD3ε APC-
eFluor 780 (clone 145-
2C11) 
Figure S3 (Total Thymocytess analysis), Figure S4A-B (Depleted Splenocytes 
analysis), Figure S4C-D (Total Thymocytes and Splenocytes analysis) 
Anti-mouse TCRβ eFluor 
450 (clone H57-597) 
Figure S4A-B (Depleted Splenocytes analysis), Figure S4C-D (Total 
Thymocytes and Splenocytes analysis) 
Anti-mouse CD49b Biotin 
(clone DX5) 
Figure S4 (Depleted Splenocytes analysis) 
Anti-mouse CD62L APC 
(clone MEL-14) 
Figure S4A-B (Depleted Splenocytes analysis), Figure S4C-D (Total 
Splenocytes analysis) 
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Anti-mouse CD45.2 
Brilliant Violet (clone 104) 
Figure S4C-D (Total Thymocytes and Splenocytes analysis) 
Anti-mouse CD4 eFluor 
450 (clone GK1.5) 
Figure S4C-D (Total Splenocytes analysis), Figure S5 (Total Thymocytes 
analysis) 
Anti-mouse CD45 eFluor 
450 (clone 30-F11) 
Figure 5A (BM-derived DNs analysis) 
Streptavidin PerCP-
Cyanine5.5 
Figure 2 (BM-derived DNs sort), Figure 3D (Thymocyte DNs sort) 
Streptavidin Brilliant Violet 
510 
Figure 6A (Thymocyte DNs sort and analysis), Figure 6B (FL DNs analysis), 
Figure S3 (Total Thymocytes analysis), Figure S4 (Depleted Splenocytes 
analysis)  
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Movie S1: Timelapse movie of clonal DN2 progenitor lineage, Related to Figure 2.  
Bcl11b-YFP-mCh- DN2 progenitors were cultured on OP9-DL1 monolayers with 5 ng/mL IL-7 
and Flt3-L within individual PDMS micro-wells, and continuously imaged for 100 hours.  
Images show superposition of a DIC image (gray) and cellular fluorescent intensities from the 
Bcl11b-mCherry (red) and Bcl11b-YFP (green) channels, with segmented cell boundaries shown 
in white.  For clarity, images show only the fluorescence intensities within the cell boundaries, 
excluding auto-fluorescence from well boundaries and OP9-DL1 monolayers.  Scatter-plot 
(bottom-right) updates with each frame to show fluorescent intensities of segmented cells at 
corresponding time points.  Scale bar = 50 microns. 
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   Figure S4 (continued)
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Figure S6
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Mathematical Appendix
We describe a series of dynamical models that aim to clarify the interplay between global
(trans) and locus-specific (cis) mechanisms in the control of Bcl11b activation and T-lineage
commitment. We first use these models to understand the dynamics of normal Bc11b acti-
vation in an initial population of DN2 progenitors that are inactive for both Bcl11b copies
(Figure 4). Next, to distinguish between these different models, we will make predictions
about their behavior on a clonal lineage level (Figures 4C-D), and their responses to per-
turbations of different activation steps (Figures 5C-D and S6, S7), which we will test exper-
imentally. In these models, we do not explicitly model the ETP to DN2 transition, as our
experiments all start with cells that have already turned on CD25; however, as we discuss
below, our analysis of the sequential and parallel trans-cis models suggest that some of the
molecular events we consider could occur prior to the ETP-DN2 transition. We note that
these models are simplified representations of more complex underlying systems, and a full
understanding of the dynamics of the complete system will involve additional processes not
accounted for here. However, we use these minimal models to constrain experimental data,
evaluate the plausibility of broad classes of mechanisms, and provide a starting point for
further investigation.
Simple cis-activation model
In this model, activation of Bcl11b involves a single, slow first-order step that takes place in
cis, i.e. on the locus of the Bcl11b gene itself. This activation step is controlled independently
for two copies of Bcl11b in a single cell, and with the same rate constant. Under these
assumptions, the fraction of non-expressing, monoallelic and biallelic Bcl11b expressing cells
evolve over time according to the following dynamical equations:
1
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dn0
dt
= −2kC · n0 (1)
dny
dt
= kC(n0 − ny)
dnr
dt
= kC(n0 − nr)
dnyr
dt
= kC(nr + ny)
Here kC is the first-order rate constant of the slow cis-acting step on the Bcl11b locus. In our
experiments, starting DN2 progenitors were sorted to have no Bcl11b expression on either
copy. Thus, in our model fitting, we take all starting cells to be in a non-expressing state,
following this initial condition:
n0(0) = 1 (2)
Accordingly, all other variables are set to zero. Following this initial condition, we performed
least-squares fitting, varying kc to provide the best fit to experimental data (Figure 4A). As
seen from best least-squares fit, this model is a poor description of the experimentally ob-
served dynamics of Bcl11b activation from DN2 (Figures 4A-B): this is because the fraction
of biallelic expressing cells increases more slowly compared to that of the monoallelic ex-
pressing cells at the earliest time points. To see how this this time lag arises, we can solve
for this model analytically, to derive the following solutions:
n0(τ) = e
−2τ (3)
ny(τ) = e
−τ − e−2τ
nr(τ) = e
−τ − e−2τ
nyr(τ) = 1 + e
−2τ − 2 · e−τ (4)
2
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Where τ = kCt is time in non-dimensional units. At early time points, where τ  1, we can
expand these solutions using a power series to obtain:
ny ≈ τ (5)
nyr ≈ τ 2 ≈ n2y (6)
At early time points, the fraction of biallelic expressing cells is approximately the square
of fraction of the monoallelic expressing cells, and would therefore increase at a slower rate
relative to monoallelic expressing cells.
Sequential trans-cis activation model
In this model, two rate-limiting steps are required for activation of Bcl11b, a trans-acting
step, which occurs in the nucleus away from the Bcl11b locus, and a cis-acting step, which
occurs independently on each Bcl11b locus. The trans step precedes, and is necessary for,
the cis step. Such a model could describe a reaction scheme, where an initial limiting
step, occurring away from the Bcl11b locus, activates a regulatory factor that facilitates the
cis- activation step in a permissive fashion. This regulatory factor could be a chromatin-
modifying enzyme, a transcription factor, or any other protein that serves to enable locus
remodeling. We note that in this model, it is possible that the trans-acting step occurs
before the DN2 transition (Figure 4A, gray arrows).
There are five states, a trans-inactive state M0, where this trans factor is absent, and
four states, N0, Ny, Nr, and Nry, where the trans factor is present, and two copies of Bcl11b
exist in either active or active states. The time evolution of the fraction of DN2 progenitors
in these different states are given by:
3
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Parameter Units Best-fit Lower
bound
Upper
bound
kc 1/hr 1.9× 10−2 1.5× 10−2 2.3× 10−2
kt 1/hr 1.4× 10−2 9.1× 10−3 1.9× 10−2
m0 (fraction) 0.77 0.70 0.87
Table 1: Best fit parameters of the sequential trans-cis activation model to data, with 95%
confidence intervals, Related to Figure 4
dm0
dt
= −kTm0 (7)
dn0
dt
= kTm0 − 2kCn0
dny
dt
= kC(n0 − ny)
dnr
dt
= kC(n0 − nr)
dnyr
dt
= kC(nr + ny)
Here, kT and kC correspond to the first-order rate constants for the trans and cis-acting
steps respectively. The value of these rate constants were determined using least-squares
fitting to experimental data, subject to the constraint that the initial DN2 progenitors that
we sorted are all inactive for both copies of Bcl11b, and must exist in either trans-active or
trans-inactive states:
m0(0) + n0(0) = 1. (8)
This constraint results in one additional fitting parameter to the model. The best fit tra-
jectory is shown in the main text (Figure 4A), and best-fit parameters are shown in Table
1. Unlike the simple cis-activation model, this model can give rise to a rise in the fraction
of biallelic expressing fraction concurrent with the monoallelic expressing fraction (Figures
4A-B); thus, from least-squares fitting of experimental data alone, the sequential activation
model can plausibly explain experimentally observed population dynamics.
4
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Parallel trans-cis-activation model
In this model, cis-acting and trans-acting steps are also required for activation of Bcl11b,
similar to the sequential activation model. However, in contrast to the sequential model, cis
and trans steps occur in parallel with each other, such that they occur in either order. In this
model, the trans step could represent activation of a trans factor necessary for transcription
of a cis-activated locus. For instance, the trans-acting step could correspond to the activation
of a factor that promotes the polymerase recruitment.
In this model, there are four trans-inactive states M and four trans-active states N , each
corresponding to different states of locus activation. The time evolution of the fraction of
cells in these states are given by:
dm0
dt
= −2kCm0 (9)
dmy
dt
= kCm0 − (kT + kC)my
dmr
dt
= kCm0 − (kT + kC)mr
dmyr
dt
= kC(mr +my)− kTmry
dn0
dt
= kTm0 − 2kCn0
dny
dt
= kCn0 + kTmy − kCny
dnr
dt
= kCn0 + kTmr − kCnr
dnyr
dt
= kC(nr + ny) + kTmry
Here, kT and kC correspond to the first-order rate constants for the trans- and cis- acting
steps. As experiments start with cells that do not express Bcl11b, the following constraint
describes the fitting of our models:
m0(0) +my(0) +mr(0) +mry(0) + n0(0) = 1 (10)
5
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This constraint results in four additional free parameters to the least-squares fit. Upon
performing a least-square fit to experimental data, we find that this model also recapitulates
the early rise in the fraction of biallelic expressing cells, as observed in the data (Figures 4A-
B; see Table 2 for best-fit parameter values). Of note, our model fit suggests that a significant
fraction of DN2 progenitors may already exist in a state where one or both Bcl11b alleles
are already activated in cis (Table 2). This feature of our fit will enable us to distinguish
between the sequential and parallel activation models using clonal lineage data, as we discuss
further below.
Parameter Units Best-fit Lower
bound
Upper
bound
kc 1/hr 4.2× 10−3 8.7× 10−4 7.4× 10−3
kt 1/hr 1.4× 10−2 1.1× 10−2 1.7× 10−2
m0 (fraction) 0.21 0 0.54
mr, my (fraction) 0.29 0.08 0.46
mry (fraction) 0.16 0.09 0.24
Table 2: Best fit parameters of the parallel trans-cis activation model to data, with 95%
confidence intervals, Related to Figure 4
Comparative analysis of sequential and parallel trans-cis activation
models
Clonal heterogeneity analysis
So far, both sequential and parallel trans-cis activation models provide a reasonable fit to the
population dynamics of monoallelic and bialellic cell fractions starting from non-expressing
progenitors (Figures 4A-B). How can we further distinguish between these two models? So
far, we have only considered predictions based on the behavior of whole cell populations;
however, analysis of correlations within individual lineage trees can allow discrimination of
distinct dynamic mechanisms, as was demonstrated in recent work and in classic experiments
[?] [?] [?] . As these two models differ in activation state trajectories taken during Bcl11b
6
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activation, they would be expected to generate distinct distributions of allelic activation
states in single clonal lineages.
To derive Bcl11b activation state distributions expected from either sequential or parallel
activation models, we first reformulate these models (Eqs. 7 and 9) as discrete time Markov
Chains [?], where each time step represents a single cell cycle. First, letN be the total number
of states. Next, define a random state variable St, corresponding to the state of the cell at
the number t. For the sequential model (Eq. 7), the list of states is {m0, n0, ny, nr, nyr}, with
N = 5; for the parallel model (Eq. 9), the list of states is {m0,my,mr,myr, n0, ny, nr, nyr},
with N = 8. In our descriptions below, we will enumerate all the states as i = 1...N in such
a specified order.
Next, we define T , a transition matrix with N × N elements, where Tij represents the
probability of a cell transitioning from state j to state i in a single cell cycle. For a given cell
cycle time tc, we can solve the differential equations in Eq. 7 and 9 to obtain corresponding
transition probabilities, i.e. Tij(tc). In our simulations, we first solve for these transition
probabilities, using the best-fit rate constants in Tables 1 and 2. These experiments also
used a cell cycle time of tc = 20 hrs. This was chosen in accordance with the amount of
cell expansion observed in imaging experiments, though our conclusions are not expected to
depend on the exact value of the cell division time. With this transition probability matrix,
we can then simulate state transitions across a lineage of dividing cells, according to the
following formula:
Pr(St+1 = i|St = j) = Tij (11)
Here St represents the state of the cell at the (t)th cell cycle. In the Monte-Carlo simu-
lations, each cell gives rise to two cells at each cell division, and each daughter cell chooses
its fate randomly and independently from its sibling, based on this formula. This process is
repeated iteratively for every descendant from a single ancestor until a designated stopping
time (5 cell cycles, or 100 hrs, corresponding to the end of the imaging experiment), whereby
a complete lineage tree is generated.
7
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From these clonal lineage simulations, we find the sequential and parallel trans-cis acti-
vation models yield divergent predictions of heterogeneity in Bcl11b allelic activation at the
level of single clones. For the sequential activation model, non-expressing ancestors predom-
inantly generate a mixture of progeny with monoallelic expression from both Bcl11b copies
prior to biallelic Bcl11b activation (Figures 4C-D). While some clones only express a single
specific Bcl11b copy prior to biallelic activation, these clones were rare relative to those with
monoallelic expression from each of the two alleles (Figure 4D). This is because all non-
expressing progenitors still have both Bcl11b copies in a cis-inactive state; thus, upon cell
division, all daughters of a non-expressing parent retain the same probability of activating
either allele.
By contrast, the parallel trans-cis activation model gave rise to a large frequency of
clones with monoallelic expression from only one specific allele (Figures 4C-D), either red or
yellow, varying between, but not within, different clones. This reflects the accumulation of
non-expressing progenitors that have a single Bcl11b copy present in an open state, but lack
the trans-acting factors necessary to induce expression from this opened locus (58% total,
Table 2). These clones pass through a single specific monoallelic activation intermediate prior
to biallelic activation. Additionally, in the parallel activation model, a small percentage
of clones transition directly to a biallelic expressing state without first passing through a
monoallelic state (Figures 4C-D), a behavior that does not occur for the sequential activation
model. This ‘tunneling’ of non-expressing cells to a biallelic expression state reflects the
existence of non-expressing cells with both alleles open that still lack the critical trans-
acting step to enable their expression. For these cells, activation of the trans-acting step
causes both alleles to turn on simultaneously.
In our experimentally observed distributions of allelic activation states, we found that in-
dividual clones predominantly showed monoallelic expression from only one allele (Figure 4E,
7/9 clones observed), but only rarely showed monoallelic expression of both alleles (Figure
4E, 1/9 clones observed). This distribution of single-specific monoallelic clones was signifi-
8
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cantly different from the fractions predicted for the sequential activation model (p < 0.01,
χ2 = 6.8, d.f. = 1), but not significantly different from predictions for the parallel activation
model. Furthermore, the experimentally observed distributions also showed evidence for
simultaneous activation of both alleles from a non-expressing state (Figure 4E, 1/9 clones),
consistent with the occurrence of a parallel trans-activation event in a DN2 progenitor with
both Bcl11b alleles pre-activated in cis, which is only allowed in the parallel activation model.
Taken together, the experimental clonal lineage data favor the parallel activation model as
an explanation for the underlying kinetic processes controlling Bcl11b activation, suggesting
that the trans- acting step necessary for Bcl11b activation occurs in parallel with the cis-level
step on the Bcl11b locus.
Effects of perturbation of cis and trans activation steps
To further discriminate between sequential and parallel trans-cis activation events, and to
gain insights into the molecular mechanisms underlying control of the trans-acting step, we
analyzed the predicted effects of perturbing different reaction steps for each model. We then
tested these predictions by removing the Notch signaling ligand DL1, an essential T-cell
developmental signal that controls Bcl11b activation probabilities. Here, we show that per-
turbations of the reaction steps in different models generate distinct shifts in the distribution
of monoallelic and biallelic expressing cells, which can be compared to experiments for model
discrimination. In this simulation analysis (Figures 5C-D and S7), we perturbed both cis-
and trans-acting steps in the two models in the same way, by reducing its forward rate while
introducing a non-zero backward rate. This assumption of reversibility reflects our previous
observations that Bcl11b can turn back off in a small fraction of cells. We previously noted
that although Bcl11b expression maintenance rapidly becomes Notch-independent, there is
a small percentage of cells that can lose Bcl11b expression again shortly after activation, if
Notch signaling is removed [?]. Thus, building on this observation, we reduced the forward
rate constant by a fraction d, while concomitantly increasing the back rate constant by the
9
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same amount d. Also, in accordance with experimental observations1, the effect of each per-
turbation on the change in rate constants was further reduced a multiplicative factor f(< 1)
for transitions to and from a dual-allele expressing state. The perturbed rate constants are
labeled in the state transition diagrams in Figure S7, and their definitions, as described here,
as listed in Tables 3-6. We note that, while the magnitudes of the experimentally observed
shifts depend on these chosen values, the directions of these shifts in phase space upon per-
turbation - corresponding to the increases or decreases in ratio of biallelic to monoallelic
expressing cells - are not dependent on the specific values of chosen constants, and thus
represents a robust qualitative prediction of the modeling.
By numerically simulating these models, we found that different perturbations generated
distinct shifts in Bcl11b monoallelic to biallelic expression states that could then be used to
predict the site of Notch action, and distinguish between the two models. Specifically:
• When cis-acting steps are perturbed in both the sequential and parallel activation
models, non-expressing or monoallelic expressing starting progenitors reach a final state
with reduced biallelic expression, and either reduced (sequential activation model)
or increased (parallel activation model) monoallelic expression (Figures 5C and S7,
blue arrows). However, the ratio of biallelic to monoallelic expressing cells (Fb/Fm)
invariably decreases, such that the line connecting initial to final states in phase space
makes a smaller angle with the x-axis when perturbation is applied. This qualitative
result is not dependent on the exact perturbation strengths specified by d and f because
slowdown of cis-acting steps increases the time necessary for cells to achieve full biallelic
activation, and thus reduces the amount of biallelic activation at a fixed time.
• When the trans-acting step in the sequential activation model is perturbed, progenitors
starting without Bcl11b expression (Figure S7, sequential model) reach a final state
1We attenuated Notch-dependency as described because experiments showed that cells with both Bcl11b
alleles active show a reduced rate of reversion to an inactive state upon Notch signaling withdrawal. The
molecular basis for this attenuation in Notch dependency is currently unclear, but likely involves involve
a parallel process occurring in the nuclei of progenitors to stabilize a Notch-driven T-lineage program over
time.
10
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with a reduced fraction of monoallelic and biallelic expressing cells. Progenitors starting
with mono or biallelic expression are not affected (Figure S7, sequential model).
• When the trans-acting step in the parallel activation model is perturbed, non-expressing
and monoallelic progenitors reach a final state with reduced monoallelic and biallelic
expression, but also show an increase in the ratio of biallelic to monoallelic express-
ing cells (Figure 5D). As explained above, this increase in Fb/Fm cannot occur with
inhibition of the cis-acting step in either model, and cannot occur when starting with
monoallelic expressing cells in the sequential activation model. Hence, this shift distin-
guishes the parallel from the sequential activation model. Furthermore, when starting
from a biallelic expressing state, perturbation of the trans step causes direct transition
to a non-expressing state, without passage through a monoallelic expressing interme-
diate (Figure S7, parallel model). This biallelic inactivation represents the reversion of
the progenitor to a state where cells still maintain two cis-active Bcl11b alleles cis, but
have now inactivated a parallel trans-acting necessary for expression from a cis-opened
locus. As this biallelic shutoff would not be predicted to happen upon perturbation
of any other step in either model, it provides an additional signature of the parallel
activation model.
Taken together, this analysis suggests that the sequential and parallel activation models
could potentially be distinguished by analyzing changes in the fractions of non-expressing,
monoallelic, and biallelic cells in response to perturbation, if this perturbation involved a
disruption of the trans-acting step for Bcl11b expression.
To test these predictions, we sorted DN2 progenitors with different numbers of active
Bcl11b alleles, cultured them in vitro in either the presence (unperturbed condition) or ab-
sence (perturbed condition) of Notch signaling, and then analyzed allelic activation states
after four days using flow cytometry. Consistent with parallel activation model, Notch with-
drawal reduced the proportion of monoallelic to biallelic expression in cells that started with
zero or one active copies of Bcl11b (Figures 5A-B). It also caused the direct transition of
11
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bialellic expressing cells to a non-expressing state, without passing through a monoallelic in-
termediate state, as can be seen in the flow cytometry analysis of the effects of Notch removal
on progenitors expressing both copies of Bcl11b (Figure 5A, green arrow). These experiments
reveal a strong correlation at the single-cell level between expression levels of Bcl11b-YFP
and Bcl11b-mCherry alleles, in cells that are shutting off their expression, suggesting that
the inactivation of Bcl11b upon Notch withdrawal occurred in a highly synchronous manner
for two alleles. Taken together, our results support the parallel activation model over sequen-
tial activation model, and indicate that Notch signaling effectively represents one parallel
trans-acting step necessary for Bcl11b expression.
Parameter Description
k0f = kC(1− d) cis-activation rate, from non-expressing to monoallelic state
k1f = kC(1− f · d) cis-activation rate, from monoallelic to biallelic state
k0r = kC · d back cis-activation rate, from monoallelic to non-expressing state
k1r = kC · f · d back cis-activation rate, from biallelic to monoallelic state
kT trans-activation rate
d 0 to 0.35
f 0.4
Table 3: Perturbing the cis-acting step in the sequential activation model, Related to Figure
5
Parameter Description
kC cis-activation rate
k0f = kT (1− d) trans-activation rate
k0r = kT · d back trans-activation rate
d 0 to 0.35
Table 4: Perturbing the trans-acting step in the sequential activation model, Related to
Figure 5
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Parameter Description
k0f = kC(1− d) cis-activation rate, from non-expressing to monoallelic state
k1f = kC(1− f · d) cis-activation rate, from monoallelic to biallelic state
k0r = kC · d back cis-activation rate, from monoallelic to non-expressing state
k1r = kC · f · d back cis-activation rate, from biallelic to monoallelic state
kT trans-activation rate
d 0 to 0.35
f 0.4
Table 5: Perturbing the cis-acting step in the parallel activation model, Related to Figure 5
Parameter Description
kc cis-activation rate
k0f = kT (1− d) trans-activation rate, from non-expressing/monoallelic state
k1f = kT (1− f · d) trans-activation rate, from biallelic state
k0r = kT · d back trans-activation rate, from non-expressing/monoallelic state
k1r = kT · f · d back trans-activation rate, from biallelic state
d 0 to 0.65
f 0.2
Table 6: Perturbing the trans-acting step in the parallel activation model, Related to Figure
5
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